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Introduction
The concept that bacterial sepsis from oral organisms can cause infections and
disease throughout the body was first proposed over a century ago. Since then this idea
has been tested and refuted, only to re-emerge and introduce a new paradigm into
medicine and change the way clinicians view oral infections. Historically, dental
infection was not considered among infections that could pose a potential health risk to
an individual. Today, the prescribed prophylaxis guidelines from the American Heart
Association are intended to protect the high-risk patient from developing bacterial
endocarditis following dental procedures that could cause a bacteremia, i.e., heart valve
replacement and prosthetic joint replacement. Thus, oral treatment and oral infections
have come to be viewed as procedures that could possibly have adverse effects on pre-
existing medical conditions.
The periodontium is an organ that is highly vascular and yet highly contaminated
with organisms that can be a source of infection. The soft tissues of the periodontium can
become engaged in an inflammatory response that can release or clear a variety of
biologically active molecules into the systemic circulation. The periodontium provides a
concentrated reservoir for these inflammatory mediators that is constantly undergoing
exchange with the oral en'vironment and the surrounding tissues.
Many studies have attempted to link periodontal disease with various systemic
disorders. For example, diabetes mellitus patients who exhibit poor blood glucose
control, have been found to develop periodontitis at higher incidence rates and greater
interproximal loss of connective tissue and alveolar bone loss than patients who are non-
diabetic or are well-controlled diabetics [1]. Diabetes has direct effects on the immune
1
2response by affecting PMN adherence, chemotaxis and phagocytosis, which eventually
result in less effective microbial defense mechanisms [2]. The binding of end products
such as AGEs (advanced glycation endproducts) to monocytes results in the production
of catabolic and inflammatory mediators that potentially contribute to deleterious effects
on the periodontium [3].
Vascular diseases represent another group of diseases in which clinicians have
attempted to establish an association with periodontal diseases. Vascular diseases
continue to be responsible for more deaths in the U.S. than any other human disease.
Arterial disease, specifically atherosclerosis, has claimed more lives than any other
systemic condition. The prevalence and severity of atherosclerosis is related to a number
of factors some of which are heritable and thus not modified by behavior. Other risk
factors are acquired and can be modified. Hyperlipidemia is one of the most significant
risk factors for development of atherosclerosis and to some extent can be modified by
diet, exercise, or drug therapy. The atherogenic process is perpetuated by long standing
elevated serum lipid levels, is chronic and over time results in severe thickening of the
vessel wall with changes in arterial compliance and lumen diameter [4]. An intimate
relationship exists between a bacterial insult and the body's own immunity, that is
responsible for perpetuating infection-associated atherogenesis and thromboembolism.
Studies have revealed that infusion with bacterial products up-regulates the expression of
endothelial adhesion molecules, triggers the release of inflammatory mediators and
favors coagulation and thrombosis [5]. These mediators have been found to enhance
lipid accumulation within immune cells and ultimately lead to thickening of arterial
walls.
3There are many chronic inflammatory diseases in humans that possess similar
features to atherosclerosis. For example, periodontal disease is an oral disease, most
commonly chronic, that results in the release of inflammatory mediators, interleukin-l~,
interleukin-6, interleukin-8, tumor necrosis factor-a., prostaglandin E2, and matrix
metalloproteinases, that have adverse effects on the surrounding periodontal tissues.
Release of these mediators results in vasodilation and increasing vasopermeability,
inflammatory cell recruitment, connective tissue degradation, and eventual bone loss.
The periodontium in essence serves as a concentrated reservoir of potentially deleterious
proinflammatory and tissue destructive mediators.
Periodontitis represents a chronic inflammatory disease resulting from
accumulation of a primarily anaerobic Gram- negative subgingival flora,that leads to
gingival inflammation, harmful effects on periodontal tissues, loss of alveolar bone, and
eventual exfoliation of teeth [6]. Specific bacteria have been cultured from periodontal
pockets that have been shown to be highly pathogenic: Prevotella intermedia,
Bacteroides forsythus (Fannerella forsythensis), Porphyromonas gingivalis, and
Treponema denticola and others [6]. Recent studies have identified specific bacterial
lipids called ceramides in periodontally-diseased gingival tissues [7]. One specific fatty
acid component is synthesized "by organisms such as Bacteroides, Capnocytophaga,
Porphyromonas, and Prevotella genera, [8]. This fatty acid, 3-0H iso-branched C17:O, is
held in both LPS and complex lipids of these genera [8]. Most 3-0H iso-branched C17:0
is amide-linked within complex lipids of some of these organisms. Finally, 3- OH iso-
branched C 17:0 has been isolated in lipid extracts from gingival tissues and calculus of
periodontally diseased teeth [8]. In addition to being found within diseased periodontal
4tissues, 3- OR iso-branched C17:O has been recovered in atheromas [9]. 3- OR iso-
branched C I7:O is also recovered in specific sphingolipids, called ceramides, ofP.
gingiva/is and Bacteriodes fragi/is. Additional unusual or novel complex lipids or lipid
products have been reported for some of these organisms as well. The dominant class of
ceramides recovered from P. gingiva/is contains C17:1 instead of the 3-0H C17:0 found in
other bacterial ceramides, Le. B. fragilis.
Returning to the relationship between periodontal disease and atherosclerosis, the
importance of investigating this relationship between periodontal disease and
cardiovascular disease has been prompted by large-scale epidemiological studies. These
studies have demonstrated an association between periodontal disease and cardiovascular
disease after adjusting for age, triglyceride levels, cholesterol, socioeconomic status,
poverty, smoking, diabetes, and other common risk factors [10]. A recent study
examined carotid artery wall thickness by Doppler vascular studies in 15,000 subjects
and found a significant direct relationship between the severity of periodontal disease
sequella (attachment loss) and the thickness of carotid artery walls [11].
The primary concern with these recent epidemiological studies is that the criteria
used to quantify periodontal disease does not distinguish between past and persistent
periodontal infection. Depending on how periodontal organisms or host reactions to
periodontal organisms influence atheroma formation, persistence of active periodontal
infection will have a significant bearing on the development atheroma formation.
Another issue that is not resolved through the epidemiological studies is how periodontal
organisms might promote atheroma formation. There are presently two possible
explanations 1. A direct mechanism, whereby the periodontal organisms enter the
5bloodstream and directly invade the arterial walls and 2. An indirect mechanism
involving oral microorganisms entering the blood and stimulating an inflammatory
response by the host that ultimately contributes to the development of atherosclerosis
[12].
Both of the proposed mechanisms for periodontal organisms to promote atheroma
formation involve transport of either bacteria or bacterial products in the blood. The
proposed direct mechanism for periodontal organisms to promote atherosclerosis
involves periodontal bacteria entering the bloodstream and directly invading the arterial
wall. However, the arteries commonly affected by atherosclerosis are found in the
systemic circulation. For periodontal organisms to reach these arteries from periodontal
disease sites, they must be carried through the venous system to the right side of the
heart, through the pulmonary circulation and return to the left side of the heart, and
finally enter the systemic circulation. Direct invasion of artery walls by periodontal
organisms carried in blood to the systemic circulation requires the transport of organisms
through most of the circulation before artery wall invasion would occur. This type of
process appears to be unlikely. On the other hand, bacterial products, such as
lipopolysaccharide (LPS), could be released as extracellular blebs· from microorganisms
within the periodontal pocket and may enter the periodontium [13]. A bacteremia can
result from scaling and root planning or an acute or chronic abscess allowing bacteria to
gain access to the circulation. Circulating microorganisms can shed their LPS, which can
have detrimental effects on host immune and inflammatory cell function and lipid
metabolism. Cellular activation can result from LPS binding to the TLR-4 receptors, a
high.-affinity - lipopolysaccharide binding region on monocytes and endothelium, and at
6the vessel wall. Cellular release of chemokines and cytokines as a result of this binding,
can result in the upregulation of adhesion molecules at the vessel wall [13]. Leukocyte
infiltration and proliferation of smooth muscle cells could then follow and proliferation of
the atheromatous lesion could occur.
Another possible indirect mechanism involving periodontal organisms influencing
atheroma formation, involves the release of proinflammatory mediators from host
immune cells as a result of bacterial activation. Secondary to periodontal infection,
cytokines and other proinflammatory mediators can be released by immune cells in
response to a stimulus. One of these potential stimuli is LPS, which is present in
subgingival plaque associated with periodontal disease [14]. Bacterial components along
with LPS can activate the release of a cascade of inflammatory cytokines, which can
induce the liver to produce acute-phase proteins and thereby playa role in atherosclerotic
development [14]. For example, acute-phase proteins such as C-reactive protein and
fibrinogen, affect coagulation, platelet activation and aggregation [14]. LPS and
inflammatory cytokines may also increase the expression of intercellular adhesion
molecules by endothelial cells that are associated with atheroma formation.
If periodontal microorganisms directly affect the arterial walls, one would assume
that removal of all teeth, presumably periodontally involved teeth, should result in a
reduction in the risk of suffering from a heart attack. However, epidemiological studies
revealed that subjects with no teeth were at the same risk of suffering a heart attack or a
stroke when compared with age-matched subjects with periodontal disease [15]. One
explanation for this phenomenon could be that edentulous patients were exposed to
periodontal microorganisms before the teeth were lost and the bacterial by-products may
7have persisted within atheromas long after tooth extraction. This assumes that the
bacterial factors that persist in atheromas are relatively stable to metabolic breakdown
and that they possess biological activity. Since atheromas are heavily laden with lipid
deposits, a bacterial factor that is lipophilic would probably have the greatest potential to
invoke such a process. Evidence will be provided in this thesis to support this later
possibility.
Assuming that bacterial lipids are involved in atheroma formation, another
question arises regarding the source of the bacterial lipid responsible for progression of
the atheromatous process. Given the frequency of bacteremia from periodontal microbes
in subjects with periodontal disease, it seems likely that periodontal organisms could
participate in such a process. If so, then the bacterial lipid that is extracted from the
plaque samples from subjects with known atherosclerosis should parallel the bacterial
lipid extracted from the carotid atheromas. Evaluating the level of attachment loss and
remaining available teeth, through periodontal examinations, can provide information
about the patient's periodontal disease experience. Radiographic analysis of the patient's
dental records prior to tooth extraction can provide clues regarding the history of tooth
loss. Correlating the presence of the same bacterial ceramides in the plaque samples,
collected ·during a periodontal exam, with those of the endarterectomy samples can
provide insight into paralleling biological effects at different sites within the body and
support a possible role of organisms as potential contributors of bacterial lipids to
atheromas. Stated another way, this model could explain how bacterial contamination at
one site in the body could affect the progression of disease at another site.
Literature Review
Pathogenesis of atherosclerosis
The term atherosclerosis stems from the Greek word athera meaning, "gruel or
porridge like" and thus characterizes the main feature of this disease, i.e., the formation
of intimal fibrofatty plaques that have a central core rich in lipid and connective tissue
[4]. These intimal plaques, otherwise known as atheromas, protrude into the lumen, at
bifurcation areas and bend into the vessel, weakening the underlying media, predisposing
the vessel to thrombosis, aneurysm, and impairing the vessel's elastic properties. The
fibrofatty lesion consists of a fibrous capsule, a thick layer of fibrous connective tissue,
and a necrotic tissue mass and lipid aggregate in the middle of the lesion [4].
Atherosclerotic plaques begin with the accumulation of lipids (cholesterol esters derived
from low-density lipoprotein). Monocytes adhere to and penetrate the endothelium
during the early stages of atheroma formation [16]. Adhesion molecules, chemotactic
cytokines, and proinflammatory cytokines facilitate the adherance process. Eventually
these macrophage cells become engorged with oxidized low-density lipoproteins,
becoming foam cells [17]. Within the lesion the monocyte transforms into macrophages
and releases proinflammatory cytokines [17]. Intramural thrombosis may result from
monocyte stimulation or the atheroma itself may enlarge through the release of platelet-
derived growth factor and other gro'Wth factors. Fibrin is also involved in the process
through the release of mitogenic and chemotactic factors that result in the production of a
fibromuscular cap underlying the endothelium [19]. The integrity of the endothelium is
8
9eventually lost as the lesion progresses and in advanced cases stasis and thrombosis
associated with the fibrous capsule rupture leads to occlusion of the vessel.
Chronic inflammation is central to the disease process involved in the
development of atherosclerosis and may lead to degradation ofcritical tissues that
maintain vascular health. Some of the elements involved in this inflammatory process
are oxidized low-density lipoproteins, infectious microorganisms, leukocytes, cytokines,
chemokines, and phagocytes [13]. For example, P.gingivalis, a periodontopathic
bacteria, induces foam cell formation in macrophages and bacterial induction of matrix
metalloproteinase -9 from plaque macrophages which could result in the weakening of
the fibrous caps which has been implicated in plaque lysis [13]. Rupture of the fibrous
cap appears to be important in an acute coronary syndrome.
Any artery may be affected, but the major targets are usually the aorta, coronary
and cerebral arteries. Coronary atherosclerosis causes ischemic heart disease and if
thrombosis occurs may result in myocardial infarction. This alone, is responsible for
20-25% of all deaths annually [4].
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The Artery Wall: StructurelFunction
The artery wall is an entity that is dynamic, capable of rapid and adaptive
changes. '[he histologic appearance of the vessel undergoes alterations from infancy to
maturity. As early as the 34th week of gestation, these changes in the vessel wall
competence are apparent [20]. There are three basic layers to the vessel wall- the intima,
the media, and the adventia. The layer closest to the luminal edge consists of connective
tissue, smooth muscle cells, and a few macrophages is termed the intima [20]. The
boundaries of this layer, span from the luminal endothelium to the internal elastic lamina.
The intima has two sublayers; a proteoglycan layer comprised of smooth muscle cells and
macrophages, and a musculoelastic layer composed of smooth muscle cells and elastic
fibers [20]. The muscular part of the arterial walls is the media and is mostly comprised
of smooth muscle cells and elastic lamina, collagen fibrils, and proteoglycans [20].
These layers can become distinct during intimal thickening as a result of growth and
aging in the arterial system. The morphological features of this process involve the
splitting of the internal elastic lamina followed by migration of smooth muscle cells into
the space between the elastic fibers [20]. This change in the intima occurs in areas of
high arterial pressure and is seen as a "functional adaptation" of the vessel [20]. A loose
network of collagen and elastic fibers containing blood vessels, lymphatics, and nerve
fibers encases the medial layer and is called the adventiallayer [4]. The intimal
endothelium functions as a. semi-permeable membrane that controls the transfer of
molecules of varying size into the arterial walls. Labile junctions exist between
endothelial cells that widen under the influence of hemodynamic stress situations, such as
hypertension [20]. Endothelial cells for the most part are involved in maintaining a
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nonthrombogenic blood to tissue interface under the influence of prostacyclin, heparan
sulfate, endothelin, angiotensin II and thrombomodulin-thrombin complex, a regulator
of vascular tone, by making endothelial-derived relaxing factor (EDRF) [17].
Endothelial cells are also modulators of immune and inflammatory factors via cytokines
and growth factors such as IL-I, IL-6, IL-8, PDGF, FGF, CSF, TGF-~ and produce
extracellular matrix molecules such as collagen, fibronectin, laminin, and proteoglycans
[17]. The endothelium modifies lipoproteins that enhance foam cell formation and
express adhesion molecules such as monocyte chemoattractant protein (MCP-l).
ThrolTlbosis can be initiated through mechanical denudation of the endothelial lining that
results in the exposure of blood to the subendothelial connective tissue. Endothelial cells
can be activated by a number of factors including, cytokines, growth factors, and
vasoactive mediators such as histamine, serotonin, hemodynamic stress, glycosylation,
and viruses [20].
Vascular smooth muscle cells, as the major component of the arterial media, are
capable of many functions including, vasoconstriction and dilation in response to
pharmacologic stimuli, synthesis ofvarious types of collagen, elastin, and proteoglycans
[20]. Smooth muscle cells are also key players in the atherogenic process by migrating
from media to intima, proliferating in response to inflammatory factors, and participating
in lipid and phospholipid metabolism by uptake and degradation of lipoproteins [4].
Migration and proliferation of smooth muscle cells is dependant on certain promoters and
inhibitors. Promoters include platelet-derived growth factor (PDGF), basic fibroblast
growth factor (b-FGF), and illterieukin-I (IL-I) [13]. Another important promotor is
mammalian ceramides, that activate smooth muscle cell proliferation through a
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sphingomyelin-ceramide signaling pathway [21]. Inhibitors include heparan sulfates,
nitric oxide, endothelium-derived relaxing factor (EDRF), interferon-gamma (INF-y)
and transforming growth factor- ~ (TGF-~) [13]. Vascular injury can stimulate smooth
muscle cell growth by altering the balance between smooth muscle cell growth inhibition
and growth stimulation. In addition, increased uptake and decreased degradation ofLDL
results in the accumulation of large amounts of lipid within smooth muscle cells,
resulting in foam cell formation. Reconstruction of a damaged vascular wall, including
endothelium, leads to intimal thickening that can become exaggerated resulting in
stenosis or occlusion of small and medium sized blood vessels.
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Atheroma formation
The principal cells in the initial lesions and fatty streak formation are
macrophages. They are critical in the formation and in the stability of the advanced
atheroma. Initiation of atherosclerotic plaque formation is thought to involve focal
accumulation of lipids, cholesterol esters derived from low density lipoproteins and very
low-density lipoproteins, and other intimal plasma proteins [13]. LDL accumulates over
time and free-radical oxidative metabolites of endothelial cells and monocytes initiate
lipid oxidation within the LDL particle. This initiates a cascade of events that results in
fatty streak formation. Oxidized LDL induces vascular cell adhesion molecule-1
(VCAM-1), and intercellular adhesion molecule-1 (ICAM-I), that stimulate endothelin
production and activate monocyte chemotactic protein-1 (MCP-1) transcription [22].
Oxidized LDL damages arterial endothelium, enabling more inflammatory cells to
migrate to the site and increases the expression of macrophage colony stimulating factor,
which stimulates the conversion ofmonocytes to macrophages in the intima layer [23].
Monocytes adhere to and penetrate the endothelium during the early stages of
atherosclerotic plaque formation, aided by adhesion molecules, chemotactic cytokines,
and proinflammatory cytokines. Monocytes become macrophages within the lesion and
may further the inflammatory process by releasing tissue degradative enzymes. The
monocyte is the most critical cell in this entire process because it releases
proinflammatory cytokines such as lL-1, IL-6, TNF-a., that inhibit lipoprotein lipase, thus
resulting in lipemia [13]. It also releases IL-8 that aids in the recruitment of more
leukocytes to the area. IL-1 and TNF-a are also released by T-Iymphocytes that signal
macrophages to release MMP, further contributing to the degradation of endothelial
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integrity of the vessel wall. Upregulation of these cytokines is prominent in chronic
infection and also in severe sepsis syndromes. As macrophages accumulate within the
intima, they ingest oxidized LDL as well as smooth muscle cells from the tunica media.
At this stage they are known as foam cells [24]. Platelets aggregate at the site of
endothelial injury as the lesion progresses, along with smooth muscle cells and
macrophages. Platelets release PDGF, FGF, and TGF-p, thereby propagating the
synthesis of extracellular matrix molecules such as collagen, elastin, and glycoproteins
and promoting cell proliferation [25]. Once the foam cells aggregate with extracellular
lipid and become surrounded by smooth muscle cells, and fibrous tissue, it is known as a
fibrofatty atheroma. Atheromas are capable of undergoing transformation whereby they
can become calcified. Calcification of the atheromas is a characteristic of advanced and
long- standing atherosclerosis. It was thought that mineral deposits were formed through
a physical process of nucleation of hydroxyapatite in the vesicles of dea.d cells, followed
by crystal growth into the extracellular matrix, very similar to what occurs during
calculus formation around teeth [20]. Currently, the accepted theory is that the calcium
deposition is controlled partially via cells, such as macrophages and mast cells, and
cellular proteins, such as bone Gla-protein and bone sialoprotein [20]. In late stage
atherosclerosis, rupturing of the endothelium lining leads to thrombus formation,
occlusion of the arterial lumen, and intraplaque hemorrhage. Fibrin degradation products
appear to be involved in both the thrombotic events and have chemotactic and mitogenic
properties that propagate the lesion and lead to smooth muscle cell proliferation [26].
This smooth muscle cell proliferation leads to the formation of a fibromuscular cap
beneath the endothelium and further vessel wall ischemia.
15
The process of atheroma formation would occur rather quickly if it weren't for the
body's own hemostatic properties. LDL oxidation is inhibited by HDL, high-density
lipoprotein, through the release ofplasmologens such as platelet activating factor [22].
Monocytes and macrophages, also mentioned in the destructive process, clear oxidized
LDL by possessing specific receptors that scavenge the free lipid. It is this balance
between the protective factors and the deleterious ones that ultimately determines
whether the atherosclerotic plaque will fonn. This is also dependent upon the extent of
hyperlipidemia present that tends to overburden the system.
16
Risk Factors for Atherosclerosis
Of all the factors that have been implicated in having an effect on the process of
atherogenesis, age has the strongest and most consistent association. The initial lesion,
characterized by isolated macrophage foam cells, appears at infancy and lasts through the
first decade of life. Fatty streaks are evident by the first and second decade of life [27].
Atheroma formation and potentially symptom producing lesions typically occur during
the third decade of life [27]. Large-scale epidemiological studies have revealed very
clearly that coronary heart disease during the middle decades of life is far more common
in men than in women [20]. Large-scale epidemiological studies have revealed very
clearly that coronary heart disease during the middle decades of life is far more common
in men than in women [20]. This gender differential decreases with age, but never
disappears completely [20]. The incidence of coronary infarction is at least four to five
times higher in men compared to women until women experience menopause.
Thereafter, the rate of atherosclerosis development in women approaches that observed in
males. High levels of circulating estrogens have proven to be the protective factor in this
observation through indirect effects on lipoprotein metabolism and direct effects on the
vessel wall itself. Functionally competent estrogen receptors have been identified in
vascular smooth muscle cells, and specific binding sites have been characterized in
endothelium. Dogs injected with high levels of testosterone exhibit lower plasma levels
of anti-arteriosclerotic high-density lipoproteins [29]. Two studies on HDL in children
indicate that until the age of eleven or twelve, boys have higher mean concentrations of
HDL than do girls [30]. After the age of twelve, a decrease in plasma concentrations of
HDL takes place in males, and an increase in females [27,30].
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There are striking geographical variations in the prevalence of coronary heart
disease. In general, a higher standard of living predisposes individuals to a greater risk
of developing CHD and other atherosclerotic-induced disorders. Western
industrialization has provided people with the luxury of many types of foods high in
saturated fats. The portions of food served at restaurants are at their highest or often
contain foods rich in saturated fat. A growing problem in this country is the expanding
population of obese children. Parents apparently fail to prevent their children from eating
high-fat foods. It seems that socioeconomic and cultural factors feed into this dilemma.
Fast-food eating comprises most American diets due to the fast pace lifestyle of most
Americans and its relatively low cost. In addition, red meats and high carbohydrate diets
are central to the cuisine of many cultures.
Although a familial genetic factor does exist, development of atherosclerosis
mostly relates to a prior history of other risk factors such as hypertension and diabetes.
In other instances, it may be a hereditary genetic derangement in lipoprotein metabolism
that results in excessively high blood lipid levels. Familial hyperlipoproteinemias,
autosomal dominant genetic disorders, are present in 1 of every 500 individuals in the US
[31]. Delaying treatment for such a condition inevitably leads to atherosclerosis
development.
There are four major acquired risk factors that are amenable to control:
hyperlipidemia, hypertension, cigarette smoking, and diabetes. Hyperlipidemia is a
condition that results from high-cholesterol or high-fat diets. The major lipids in
atheromas are cholesterol and cholesterol esters derived from plasma [4]. Epidemiologic
studies have revealed that the higher the total cllolesterollevel, the greater the risk of
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symptomatic and fatal atherosclerotic disease [20]. High-density lipoprotein (HDL)
levels participate in the reverse transport of cholesterol and mobilize this lipid from
cells, presumably from atherosclerotic plaques, transporting it to the liver for excretion in
the bile.
Hypertension is a powerful incremental factor in atherogenesis. Hypertension has
been shown to be associated with an increased extent of fatty streaking in both the
abdominal aorta and the coronary arteries [20]. Its manifestation is attributed to
alterations in the intra-arterial pressure. Increased intra-arterial pressure alters the
metabolic characteristics within the artery wall leading to endothelial injury resulting
from disturbances in flow patterns and increased endothelial permeability [20].
Many studies have reported the adverse effects of smoking on the progression of
peripheral vascular disease. Prospective studies have shown that men aged 40-49, who
smoke more than 40 cigarettes a day, run a five times greater risk of dying from ischemic
heart disease than age-matched non-smokers [32]. A number of possibilities have been
proposed to explain the associated risk carbon monoxide has on the intima layer of the
vessel. Increased accumulation of cholesterol has been observed in the aortic walls of
animals fed a standard diet of daily cholesterol, but exposed to carbon monoxide [32].
Carbon monoxide induces shrinkage of endothelial cells lining the arterial lumina. Gaps
are created amongst the cells, permitting VLDL, LDL, and chylomicrons and blood
platelets to enter the intima [33]. They can become entrapped within the intercellular
layers and accumulation can eventually block off access to oxygen and nutrients to cells
of the artery. Smoking has also been shown to affect platelet aggregation. Studies have
revealed that coagulation times of smokers are significantly shorter than those of non-
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smokers [20]. Platelets can either simply aggregate as a result of cotinine exposure or
lead to thrombus formation [31] . Formation of emboli within the artery can lead to
platelets releasing granules of pro-inflammatory substances. Incipient lesions can begin
to form at this point or a previously existing lesion can be further propagated.
Diabetes mellitus (DM) is a known major contributing risk factor, which is
characterized by reduction in or lack of production of insulin. The individual is at risk
for altered glucose tolerance, impaired lipid and carbohydrate metabolism with resultant
hyperglycemia. Type II Diabetes affects 10 million Americans, with 50% undiagnosed,
10% who are older than 65, and 80% who are overweight [2]. Diabetes has profound
negative effects on the vasculature and increases the risk for atherosclerosis. Diabetes
causes a disruption of fatty acid metabolism, resulting in hyperlipidemia and the
formation of advanced glycation endproducts [3]. Patients with adult periodontitis often
have elevated serum triglyceride levels. Prolonged hyperglycemia results in the
formation of advanced glycation endproducts (AGEs). AGEs are responsible for many
diabetic complications including retinopathy, neuropathy, and nephropathy [2]. AGE
products alter.the solubility of collagen and may playa role in the changes that occur in
both large and small vessels. This eventually results in poor wound healing and
predisposes the patient to atherosclerosis with resulting cardiovascular complications.
Lalla and coworkers found that the interaction of AGEs with their respective receptors
RAGEs, found on mononuclear phagocytes, upregulate the activity of the cell [3]. AGE
products binding to phagocytes not only results in a hyper-response to a gram-negative
bacterial challenge, but also increases production of pro-inflammatory mediators or
cytokines such as TNF ,IL-l ,and II-{{3]. Accumulations of AGE products results in
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an alteration and thickening of the basement membrane of blood vessels [3, 34, 35] This
alteration inhibits the exchange of nutrients, PMN migration, and oxygen in the DM
patient, resulting in the development of periodontal disease and impaired wound healing.
The risk of suffering an MI is twice as high in diabetics when compared with non-
diabetics [31]. A two-fold increase in VLDL and LDL with a doubling in plasma
cholesterol is observed in diabetic patients [31]. There is an increased risk of stroke seen
also in diabetics and a 100-fold increased risk of atherosclerotic-induced gangrene of the
lower extremities [31].
The traditional risk factors mentioned thus far account for only 50-60% of the
cases of cardiovascular disease [36]. It has been postulated for much time now that there
is an association between atherosclerosis and infections. It is a rational idea in the sense
that atherosclerosis is associated with signs of chronic low-grade inflammation.
Controlled studies have shown that milder bacterial infections including respiratory
infections, C. pneumoniae, increase the risk of stroke [37]. The evidence that provides
an association between C .pneumoniae and CHD is far stronger than any other infectious
organism. Using diagnostic techniques such as ELISA, PCR, and electron microscopy,
has revealed this organism within athersclerotic plaques. Reviewing published
epidemiological studies on the prevelance of antibodies to C.pneumoniae and CHD
revealed a 2-fold or larger association between antibody production and CHD
incidence[38]. For an infectious organism to be a part of the pathogenesis of
atherosclerosis, it would have to be chronic, persistently active, but low-grade. The
longitudinal and cross-sectional studies that have revealed a moderate association
between periodontal infection and cardiovascular disease, have used indirect measures
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and very few studies use strict criteria in their periodontal assessments. The mechanism
for periodontal disease involvement has yet to be defined.
Other associated risk factors of atherosclerosis that have been difficult to
quantitate include, insufficient physical activity, stress, obesity, oral contraceptive use,
hyperuricemia, high carbohydrate intake, and hyperhomocysteinemia. As is obvious,
multiple factors have been implicated to impose an additive effect. Placing any three of
these risk factors together, increases the heart attack rate seven times more than when
none of them are present.
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Doppler Ultrasound: Detection Techniques
Doppler instrumentation has been used for decades and was originally used for
obstetrical heartbeat monitoring. Today it is used widely to detect turbulent flow patterns
in peripheral vascular disease and flow through the heart and associated vasculature. It
can provide a clinician with information regarding the degree of stenosis, the length of
the lesion, and the characteristics of the plaque [39]. It is a non-invasive repeatable
technique that can detect stenosis proximal and distal to the carotid bifurcation [39].
The physics behind the Doppler effect is one we often take for granted in the
many high-pitched noises we hear daily, and that is a shift in the apparent frequency of a
sound wave due to the relative motion between the sound source and the observer. When
this is applied to blood flow through a vessel, instead of sound being generated by a
moving particle, the sound is sent by an ultrasonic transmitter to the moving particles of
blood that are reflected back to the observer or receiving transducer. The widtll of the
active Doppler- sample volume is determined by the focal characteristics of the
ultrasound transducer [40]. This is designed to restrict the insonated region to a pencil
size beam. The speed of sound in tissues is around 154,OOOcm/sec, and the speed of
blood is usually less than 125cm/sec in blood vessels, other than the aorta [40]. Since
ultrasonic frequency is usually in the audible kilohertz range, probes containing 5-10
megahertz transducers are available. The low-resolution (5 MHz) imaging transducers do
not allow differentiation of atherosclerotic plaque characteristics, but only assist the
placement of the Doppler sample volume. The higher-frequency (7.5-10MHz) imaging
devices attempt to derive information about the atherosclerotic plaque from the image.
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This frequency level transducer provides the maximal resolution because the carotid
bifurcation is 20-40mm beneath the skin surface.
Doppler systems are available in two basic configurations; continuous wave or
pulsed [40]. The basic disadvantage with regard to the continuous wave is the Doppler-
shifted signals are generated from all points along the path of propagation of sound where
there is a moving target. Thus, if a continuous beam was passed through an artery and
then through a vein, the Doppler-shifted signals would be combined and differentiation of
the signals would be impossible. The pulsed Doppler system samples flow at discrete
points within the vessel. This is also referred to as range-gating, and is accomplished by
turning the Doppler receiver on only at a specific point in time to accept echoes returning
from the pre-selected location along the path of propagation of the incident Doppler
beam.
The scamling protocol involved in Doppler ultrasoWld involves B-scan imaging
and is accomplished in the transverse and sagittal plane. The patient lies in a supine
position with their neck hyperextended and the head rotated away from the carotid being
examined [40]. Scanning is initiated in the transverse plane anteriorly, low on the neck,
with the probe moving anteriorly to posteriolaterally, in an attempt to best optimize the
course of the common carotid artery, carotid bifurcation, and the proximal internal
carotid artery [40]. Simultaneously Doppler sampling and sagittal B-scan images are
obtained, beginning in the common carotid artery and then sampling through the carotid
bifurcation into the proximal internal carotid artery [40]. Data are recorded from the
common carotid artery, the point of rmaximum stenosis, the internal carotid artery, and
the external carotid artery. The degree of stenosis derived from the transverse diameter
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measurements and supported by the Doppler data is then categorized into 20%
increments for angiographic comparison (0-20 %, 21-40%,41-60%, 61-99% and
occlusion).
Duplex scanning in the examination of carotid artery disease has evolved
dramatically over the past five years. This technique can demonstrate a normal carotid
artery bifurcation or carotid bifurcation with minimal atherosclerotic disease. It is
important to understand that the primary reason for the evolution in diagnostic testing
from intravenous angiography to duplex scanning was to decrease the incidence of
stroke. Currently, Duplex is shown to be accurate in grading varying degrees of stenosis
and has been successful in the early detection of atherosclerosis.
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Pathogenesis of Periodontal Disease
About 75% of the United States population is affected by some mild form of
periodontal disease, with more severe forms affecting 20-30% of the population [36].
Studies have suggested that periodontitis progresses in episodes of exacerbations and
remission. More recent studies have suggested that the progression may be more
continuous than episodic. Current evidence supports the conclusion that a relatively
small proportion of the population will experience generalized advanced destruction
through the progression of periodontitis and the progression of the disease is probably
continuous or with brief episodes of localized exacerbations of attachment loss with
intervening periods of remission [41].
Periodontal disease is a bacterial-induced inflammatory reaction. The destructive
nature of the disease is dependant on multiple factors including the type of bacteria
involved, the host's immune system, and the overall condition of the intraoral
environment. As the supragingival plaque, composed of mostly Gram-positive
pathogens, continues to increase in mass due to lack of oral hygiene, it transforms the
subgingival ecological niche to support colonization by Gram-negative anaerobic
organisms. This class of bacterial species initiates periodontal inflammatory reactions
within the periodontal pocket, either alone or in combination. Such species include
Actinobacillus actinomycetmcomitans, Bacteriodes forsythus, Campylobacter rectus,
Eubacterium nodatum, Fusobacterium nucleatum, Peptostretococcus micros,
Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrecens,Streptococcus
intermedius, and Treponema sp [42]. Shifts in the microbial flora to include these
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organisms can lead to the release of many destructive mediators. Specifically, bacterial
virulence factors such as lipopolysaccharide, LPS, found within the cell wall of most of
these Gram-negative species, results in stimulation of many cell types, including
macrophages and leukocytes, to release mediators that amplify the cytokine cascade and
result in deleterious effects on the periodontium.
Clinical signs of gingivitis begin within 10-20 days after withdrawal of plaque
control measures [43]. This varies from individual to individual and is dependant upon
intrinsically resistant factors. The clinical characteristics at this stage are gingival
redness, swelling, and an increased tendency for the tissue to bleed on gentle probing.
The histopathologic changes are far more impressive in the alterations observable within
the vascular network. Vascular beds open, exudative fluid and proteins swell the tissue
and an influx of chronic inflammatory cells is seen in the connective tissue, subadjacent
to the junctional epithelium [44]. The cells mainly comprise lymphocytes, macrophages,
and neutrophils. As the lesion begins to progress, the gingival cre\l'icular fluid flow rate
increases. Noxious substances released from microbes penetrate into the tissues from the
crevice. Defensive proteins such as antibodies, complement and protease inhibitors
escape the microcirculation. Simultaneously, leukocyte migration from the dentogingival
vascular system is enhanced by ICAM-I and ELAM-I expression (endothelial leukocyte
adhesion molecule) and other adhesions [44]. These factors facilitate leukocyte
migration and emigration to the site of the microbial challenge. Leukocytes infiltrate
primarily adjacent to the junctional epithelium and gingival sulcus region. In addition,
neutrophils appear to enter the sulcus region aided by junctional epithelium expression of
ICAM-l and host and microbial chemoattractants [44]. As the lesion progresses, so do
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the clinical and histologic manifestations of the inflammatory response. The vessels
apical to the junctional epithelium dilate, leukocytes and neutrophils increase in number,
and fibroblasts demonstrate pathologic changes. Collagen destruction occurs in the
infiltrated area and is a direct consequence of the cellular infiltrate promotion of
connective tissue matrix breakdown. The basal cells of the junctional and sulcular
epithelium proliferate and represent an innate attempt of the body to protect itself from
the plaque front. Inflammatory exudate increases and leukocyte migration into the
surrounding tissues results in edematous swelling. At this point, the lesion is established,
as defined by Page and Schroeder, and is dominated by the plasma cell. Collagen loss
continues laterally and apically as the cellular infiltrate expands in volume [45]. The
pocket epithelium becomes detached from the tooth and a heavy leukocyte infiltrate
ensues. The late stages of the inflammatory lesion are characterized by apical and lateral
extensions of the epithelium in response to plaque irritation as the anaerobic microbial
niche flourishes. The inflammatory cell infiltrate extends laterally and apically into the
connective tissue. Alveolar bone loss occurs at this point with extensive fiber damage,
apical migration of the junctional epithelium, and widespread tissue damage.
There are many unknown factors, related to temporal events in the inflammatory
reaction, in the progression from health to gingivitis and on to periodontitis. The
components of the inflammatory and the immune processes interact closely in the
pathogenesis of periodontal disease. Typically there is extensive site variability within a
patient that may be further intluenced by the innate susceptibility of the patient to
periodontal disease. The change from clinical health to an inflamed state must involve
either an increase in microbial load or a change in the host response. As the microbial
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load increases, the irritation to the periodontal tissues increases. Epithelial cells are
stimulated to produce proinflammatory cytokines. An inflammatory response begins
with the accumulation of fluid within the tissues and cell infiltration commences.
Neutrophils predominate at the beginning of the periodontal lesion. PMNs along with
macrophages and monocytes are attracted to the area. PMNs release their enzymes
causing damage and excitation of the host tissues. Macrophages participate in antigen
presentation to the B and T cells. Macrophages are critical to the disease process in their
ability to be stimulated by factors such as P. gingiva/is fimbrae and result in the secretion
of 11-1 a., IL-1 ~ and increased c-myc expression. They also possess a crucial membrane-
bound region on its cell membrane. CD-14 is a docking protein on macrophages that
supports binding of LPS, but does not stimulate macrophages to be activated. A recently
discovered transmembrane receptor, toll-like receptor (TLR-4), is involved in the
recognition and cell activation by endotoxins [46]. Furthermore, adhesion molecules,
such as ICAMs, are upregulated with exposure to LPS and these adhesion molecules
assist PMNs in their movement and attachment to the epithelium. As epithelial layers of
junctional epithelium migrate apically, a pocket forms and as the infiltrate extends
laterally, bone is resorbed. Granulation tissue forms that is vascularized and engorged
with plasma cells. Many cells within granulation tissue also produce matrix-degrading
enzymes and cytokines that directly and indirectly degrade the connective tissue and
bone. Ultimately, periodontal disease results in adverse effects on the supporting
structures of the periodontium due to the frustrated and ineffective actions of the host's
immune system in response to the accumulation of microbial plaque.
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Epidemiological evidence linking periodontal disease and cardiovascular
disease:
For a periodontal infectious agent to effect the development of atherosclerosis,
that agent would either produce a chronic or repeated infection of the atheroma site or
would need to produce a chronic, persistent activation of artery cellular constituents once
an appropriate microbial factor threshold was reached. Unfortunately there is no reliable
method of distinguishing between past infection and persistent active infection of
atheromas from periodontal organisms. An acute episode of an infectious disease may be
important in precipitating an acute cardiovascular event without necessarily being
involved in the progression or development of atherosclerosis. Longitudinal studies are
the highest form of evidence available linking periodontal disease with atherosclerosis.
Randomized clinical trials have not occurred to determine the effect of periodontal
disease prevention or treatment on cardiovascular events. There are eight studies that
have examined the relationship between periodontal disease and cardiovascular disese,
prospectively and retrospectively, with only six of them suggesting that poor periodontal
health precedes cardiovascular events [10,47-51, 52 ,53].
The most frequently cited study that examined the relationship between
periodontal disease and cardiovascular diseases was the NHANES I study. In this study,
the investigators reported that periodontal disease was a significant risk factor for
cerebrovascular accidents and nonhemorrhagic stroke [10]. Increased relative risk was
associated with periodontitis in white men, white woman, and African Americans.
DeStefano and his colleagues analyzed data from NHANES I and it's 15 year follow-up.
30
For 9,670 men and women, subjects with periodontitis had a 25% increased risk of
coronary heart disease relative to those with nlinimal periodontal disease [48]. The
study also showed that men with no teeth were 70% more likely to have Coronary Heart
Disease (CHD) than men with no periodontal disease. Among men with periodontitis,
the risk of a subject dying from a CHD event was greater than the risk for being admitted
to the hospital. These associations were independent of sex, age, race, education, poverty
index, marital status, blood pressure, serum cholesterol levels, diabetes status, body mass
index, and alcohol consumption. Men with periodontitis were found to have a relative
risk of 1.72 compared to men without periodontitis [48].
Beck and his colleagues studied 921 men, aged 21-80 years old, who were free of
CVD at baseline for a follow-up period of about 18 years [50]. They found that high
levels of alveolar bone loss at baseline were a significant predictor of total CHD
incidence and stroke. Specifically, for every 20% increase in mean bone loss, the
incidence of total CHD increased 40% [50]. Again, as in the previous study, the
association between fatal CHD and stroke and mean bone loss was in the 1.5-2.0 range.
These findings were independent of age, smoking, body mass index, serum cholesterol
levels, blood pressure, diabetes status, and education.
Joshipura and his colleagues found that the association between self-reported
history of periodontal disease and the incidence of heart disease was no longer significant
after adjusting for other risk factors [49]. Although the study found no significant
association between periodontal disease and CHD, it found a strong association between
edentulism and CHD, even after adjustments were made. The study by Hujoel and his
colleagues reviewed data from the NHANES study as did DeStefano, but extensively
31
adjusted for confounders that may have been strongly connected with infections such as
periodontal disease. Thus, the Hujoel study found a negative correlation between
edentulism and risk for CHD [53]. One of the issues that arose within this study was the
misclassification of periodontal status in these patients. The criteria defined by the study,
did not take into account the possibility of developing periodontal disease at a later point
in life.
The majority of evidence from a total of eight longitudinal studies suggests a
moderate association between periodontal disease and heart disease. Unfortunately,
insufficient evidence exists to establish a true causal relationship. With a moderate-level
association there is a concern that certain critical potential confounders and potential
effects of confounders may not have been controlled for in some studies. The other issue
is that we don't fully understand the mechanism involved in this association and we may
be controlling for potential confounders that are influenced by periodontal disease. Some
possible reasons for inconsistent findings could include the differences in ages of subjects
in the studies, smoking status not accurately adjusted for, lack of control of confounders,
residual confounding variables, over-control of confounders, the way the outcomes are
measured and the manner in which the exposure is measured. Because of the nature of
periodontal disease progression, investigators face tremendous difficulty in knowing
when a patient will develop the disease. The variety of measures that have been used in
the studies to describe the exposure have been inaccurate or poorly defined. For
example, gingivitis is overlooked as a disease category and the same subgingival
pathogens are present in gingivitis as in periodontitis except at lower levels.
32
Measurements of clinical attachment levels, is a better indicator of periodontal
breakdown secondary to periodontitis and is used now in most studies.
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Proposed Disease Mechanisms
Most or-the studies to this point have revealed a direct association between
periodontal disease and cardiovascular disease, but have not provided a biological
framework to explain the association. Infection has been recognized as a risk factor for
atherogenesis and thromboembolic events. Gram-negative bacteria when presented as a
systemic challenge, can induce inflammatory cell infiltration into major blood vessels,
vascular smooth muscle proliferation, and intravascular coagulation. In 1994, Loesche
reviewed work on periodontal disease as a risk factor for heart disease [54]. He reported
an inverse relationship between CRD and stroke and the number of teeth. He postulated
that oral diseases result in chronic infections that lead to a low-level, but frequent
bacteremias and elevated white blood cells counts. He also spoke of the effects of
exposure of the host to endotoxin that ultimately affects endothelial integrity, metabolism
of plasma lipoproteins, blood coagulation, and the function of platelets [54]. The theories
that explain the mechanism in which periodontitis affects the progression of
atherosclerosis, are controversial. There are researchers, C. Genco and others, who have
reported a mechanism of bacterial invasion of arterial walls, whereby the organism seeds
into the bloodstream and travels directly to the site of invasion [14]. Others, Beck and
offenbacher, proposed an indirect mechanism where the systemic inflammatory response
to bacterial factors such as LPS, predisposes the host to atherosclerosis [50].
Herzberg proposed a direct effect of specific oral bacteria upon entering the
bloodstream during bacteremic episodes [55]. Periodontal pathogens are not only
capable of directly invading the periodontal tissues, but cause the loss of epithelial
integrity within the periodontal pocket which creates an environment conducive for direct
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bacterial translocation and bacteremia [50]. Oral gram-positive organisms, Streptococcus
sanguis and the gram-negative periodontal pathogen P. gingivalis are reported to induce
platelet activation and aggregation through the expression of collagen-like platelet
aggregation-associated proteins [55]. This relationship could potentially help to localize
the bacterium to inflamed vascular sites. The proximity ofP.gingivalis to the endothelial
layer at inflamed vascular sites could allow this organism to attach. The macrophage,
engorged with oxidized LDL, can be stimulated by periodontal pathogens such as
P.gingivalis and B.forsythus. P. gingiva1is in turn can stimulate endothelial cell
conversion of serum LDL to oxidized LDL [56]. Another homing device that these
bacterial pathogens possess is fimbriae that may aid in their attachment to macrophages
and endothelial cells.
Recent studies have identified periodontal pathogens in human carotid atheromas
[57]. Fifty carotid atheromas, obtained at endarterectomy procedures, were examined for
the presence of bacterial DNA using polymerase chain reaction (peR), using a synthetic
oligonucleotide probe specific for the periodontal pathogens A .actinomycetemcomitans,
B. forsythus, P. gingivalis, P. intermedia. They reported that 30% of the specimens were
positive for B. forsythus, 26% were positive for A. actinomycetemcomitans, 18% were
positive for P. gingivalis, and 14% were positive for P. intermedia [57]. This study
suggests a direct role of periodontal pathogens in the development of atherosclerosis.
The findings of a recent case control study revealed that high levels of periodontal
pathogens, in subgingival plaque including B. forsythus, P. gingivalis, F. nucleatum,and
E. corrodens, are independently associated with stroke after adjusting for all known risk
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factors [5]. Another study revealed that P.gingivalis is capable of invading the coronary
and carotid endothelium in cell culture [58].
Secondary to periodontal infection, a series of soluble mediators are released
during an inflammatory response including, monocyte-derived cytokines, TNF-a, IL-I,
IL-6, and IL-8. These may indirectly affect the process of atheroma formation. Bacterial
LPS, C-reactive protein (CRP), and fibrinogen activate an impressive cascade of
inflammatory cytokines, activate platelet aggregation, and affect coagulation,
respectively [14]. Inflammatory cytokines present in periodontal disease can upregulate
the expression of factors such as intercellular adhesion molecules (ICAM), vascular
adhesion molecules (VCAM), by endothelial cells which are in turn also associated with
atheroma formation and propagation [14]. Animal studies have shown that infection with
P. gingiva/is, activates the acute-phase response, increases lipemia, and enhances
atheroma formation in Apo E (+/-) mice of heterozygous type [59]. These mice are
predisposed to atheroma formation. Injection of P.gingivalis into these same mice was
found in one study to lead to calicification of aortal atherosclerotic plaques, with the
amount of calcification increasing with the length of exposure [60]. A more recent study
has discovered specific ceramides of P. gingivalis and B. forsythus in endarterectomy
samples of patients with atherosclerosis [9]. Whether the recovery of these ceramides
indicates bacterial invasion of artery walls or bacterial lipid contamination through
undefined processes remains to be established. Perhaps phagocytic cells of blood are
responsible for transporting these lipids to the artery walls. White blood cell killing of
periodontal pathogens in blood could lead to a cascade of events including stimulation of
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inflammatory mediators and adherence of white blood cells at a distant site [9].
Ultimately, these events could alter the progression of the atherosclerotic process.
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Specific lipid recovery in endarterectomy samples:
Lipopolysaccharide, LPS, from all gram-negative organisms is comprised of a
core region and a lipid A region. The lipid A region contains aliphatic and 3-hydroxy
fatty acids [8]. Most periodontal pathogenic organisms contain 3-hydroxy mystric acid
as their predominant hydroxy fatty acid. Bacteroides species, on the other hand,
synthesize 3-hydroxy iso-branched C17:O (iso-branched 3-hydroxy-15-
methylhexadecanoate) the predominant hydroxy fatty acid. Of note 3-0H iso C 17:O is
covalently linked to complex lipids in addition to LPS [8]. It is held primarily in amide
linkage. Recovery of3-0H i CI7:O in crevicular fluid samples and gingival tissues was
originally thought to represent LPS, but was soon realized to reflect gingival
contamination with bacterial complex lipids of this shingolipid class. Recent work has
revealed that Bacteroides, Porphyromonas and Prevotella species produce 3-0H CI7 :O
which is held to a variable extent in lipids other than LPS [7]. Of note, gingival tissues
from periodontitis sites are selectively contaminated with 3-0Hi C17:0 and may
incorporate this fatty acid into intrinsic tissue lipids [8]. The elevated recovery of 3-
hydroxy iC 17:0 in periodontitis gingival tissue samples versus gingivitis samples or mildly
inflamed samples suggests that this lipid may participate in the pathogenesis of the
disease [8]. Subsequent work demonstrated that P. gingivalis incorporates 3-0H i C1 7:O
into shingolipids called ceramides. Additional investigation demonstrated that P.
gingiva/is synthesizes up to four classes of ceramides and only one class contains 3-0H
17:0. The dominant class of ceramides produced by P. gingiva/is includes C17:1 in amide
linkage to long chain bases of 17, 18, and 19 carbons in length [7]. Other organisms,
such as B. fragi/is, an organism found in the intestine, produces ceramides that are
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different from these novel ceramides recovered from P. gingiva/is. These dominant
ceramides, produced by P. gingiva/is, were shown to contaminate periodontall)i-
diseased root surfaces as well as diseased tissue samples and can directly penetrate
through contact with gingival cells without P. gingiva/is invasion [8]. The other
ceramide classes remain to be characterized structurally. Of these four classes of
ceramides recovered in P. gingiva/is, only the class containing 3-0H C17:0 does not
potentiate fibroblast or monocyte activation processes.
P. gingiva/is lipids have been examined for their effects on gingival fibroblasts.
Given the impressive recovery of lipids within periodontally diseased tissues, gingival
fibroblasts are a predominant cell type being exposed to these agents. Fibroblasts
produce many inflammatory mediators upon stimulation, including PGE2. The most
important proinflammatory effects of this mediator relate to its ability to promote bone
resorption and connective tissue breakdown. PGE2 is elevated in tissues at disease sites
and provides an indication of periodontal sites that may be at risk for break down.
Recent work, has revealed that bacterial ceramides of P. gingiva/is are capable of
promoting IL-1 f3 mediated prostaglandin secretion thereby promoting tissue destruction
in adult periodontitis [61]. Elevated cytokine levels associated with chronically inflamed
periodontal sites increase tissue PGE2leveis more in the presence of P. gingiva/is lipid
than without the lipid present [61].
Recent research has revealed the recovery OfC17:1-free ceramides in atheroma
lipid extracts , implicating that bacterial lipid contamination is primarily from P.
gingiva/is [9]. Endarterectomy samples from patients with carotid atherosclerosis has
recovered 3-0H isoC 17:0 and 3-0H iSOC I5 :0 in these samples [9]. The ratio of these
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specific fatty acids in lipid extracts ofplaque, gingival, and carotid endarterectomy
samples is virtually identical (Unpublished data). This leads us to presume that these
lipids are derived from a common source and suggests that these tissues may have been
contaminated by bacterial lipids originating from periodontal disease sites. The dominant
sphingolipid long-chain recovered in endarterectomy samples is 19 carbons in length.
The same long chain base predominates in lipid extracts from subgingival plaque samples
from teeth with mineralized bacterial debris [9]. HPLC fractionation ofP. gingiva/is
lipids reveals free ceramides ofP. gingiva/is consisting OfC17:1 (a-p unsaturated) and
either an 18 or 19 carbon long chain base, in carotid endarterectomy samples [9]. This
evidence suggests that atheromas are contaminated at least with lipid products ofP.
gingiva/is and perhaps other bacteria, and human tissue is not degrading these lipids.
This suggests that chronic introduction of these lipids may have a cumulative effect and
aid in the progression of atheroma formation.
Since it is known that these lipids are capable of potentiating or intensifying
inflammatory reactions, a sustained contamination of tissues with these lipids could
influence a coexisting inflammatory response. Removal of the source, extraction of
teeth, would be one way to eliminate the supply of lipid, but recent studies reveal that
edentulous subjects are at the same risk of developing CHD when compared with
subjects who are afflicted with periodontitis [15]. In addition, there is no definitive way
of knowing at what point in time these subjects were exposed to periodontal pathogens
that potentially irreversibly elevated their CHD risk. The evidence that periodontal
pathogens contribute to atheroma progression still remains to be explained by a
pathogenic mechanism.
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It is not clear whether other strains of P. gingivalis, other species, or other genera
of Gram-negative organisms synthesize ceramides containing C 17:1. A primary objective
of this thesis is to determine whether representative strains of Btragilis, B. forsythus
(Tannarellaforsythensis), P. intermedia and Capnocytophaga synthesize ceramides
containing C17:1. Finally, this thesis seeks to determine whether ceramides of P. gingivalis
containing C17:1 are recovered in lipid extracts of individual carotid endarterectomy
samples.
Hypothesis
Bacterial lipids derived from both specific periodontal pathogens grown in culture
and periodontal disease sites, in situ, contaminate carotid atheromas.
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Specific Objectives
Objective 1
The first objective of this study was to determine whether novel ceramides ofP.
gingivalis are contaminants of carotid atheromas in patients with prior periodontitis
experience.
Objective 2
The second objective of this study was to evaluate whether other
phylogenetically-related organisms, from the Prevotella and Bacteroides genera, can
synthesize these novel ceramides.
Objective 3
The third objective of this study was to determine whether bacterial ceramides
recovered from carotid atheromas are also present in subgingival plaque from the same
patients.
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Material and Methods
Six patients were selected based on carotid artery stenosis severity, evaluated by
Doppler ultrasound, at Hartford Hospital in a vascular surgery office. Patients included
in the study were seen for pre-surgical examination by Dr. James Gallagher, MD, a
vascular surgeon. Those subjects with severe stenosis (79-99%) of the right or left
carotid artery were included in the study. Patients were screened based on a past medical
history that excluded most systemic diseases such as autoimmune diseases, or chronic
infections. Patients that eventually fulfilled all of the criteria were asked to participate in
the study and sign a previously approved IRB consent form·. Patients that presented with
a full or partial dentition were accompanied to a nearby room within the office and
examined for periodontal attachment loss, periodontal pockets and missing teeth were
assessed. Plaque samples were obtained from all interproximal sites using coarse paper
points.
Patients who had either previous heart valve insufficiency associated with an
audible heart murmur, heart septal defects, indwelling catheters, surgically-created
vascular shunts, implanted orthopedic prosthetic appliances or other conditions outlined
by the AHA requiring antibiotic prophylaxis, received either 2 grams of Amoxicillin or
600 milligrams of Clindamycin (in penicillin allergy patients), 1 hour prior to their
periodontal exam. Antibiotic prophylaxis does not significantly alter plaque formation
during a 1-2 hour period and therefore control subjects did not require antibiotic
prophylaxis.
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Periodontal Exam: The periodontal exam was carried out by one examiner using a
Michigan probe with William's markings to measure the level of attachment, measured
from the CEJ to the depth of the pocket. Three surfaces were recorded on the facial and
three on the lingual of each existing tooth. Following the recording of all attachment
levels, plaque samples were collected from interproximal sites of all teeth. Coarse paper
points were introduced into the pockets and left in place for ten seconds. All plaque
samples were later placed in an appropriately numbered test tube. Patients were
identified only by number and vascular status.
Lipid Extraction: Carotid endarterectomy samples were previously frozen after
excision and were transported from the operation room at Hartford Hospital to the
University of Connecticut Health Center (Please see Flow Diagram 1 for an overall
description of experiment design). The samples were later thawed, minced, and placed
on a previously weighed paper boat dish. The samples were then weighed, weight
recorded, and placed in a labeled test tube.
Lipid extraction was conducted using the phospholipid extraction procedure of
Bligh and Dyer [62]. Methanol-chloroform (8 ml, 2:1 (v/v)) was added to each test tube
containing a minced endarterectomy sample, followed by the addition of2 ml of H20.
Plaque samples were immersed in 4 ml of methanol-chloroform and Iml. of H20. The
samples were then left to incubate for 3 days. At the end of 3 days, 3ml. of chloroform
and 3m!. of2N KCI + O.5M K2HP04 were added to the endarterectomy samples and
vortexed for one minute. Plaque samples received I.5ml.of chloroform and I.5ml.of 2N
KCL + O.5M K2HP04. The plaque samples were only vortexed for 1 minute, whereas the
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endarterectomy samples were centrifuged at 2000 rpm for 10 minutes. The lower organic
phase (lipid phase) was removed and placed in an appropriately labeled vile. A second
aliquote of 1.5ml of CHCL3was added to each test tube containing only the
endarterectomy samples. The endarterectomy samples were centrifuged again and the
second lipid extract was combined with the original organic extract. The plaque samples
and the endarterectomy samples were dried under nitrogen and stored at -20Co until
further processing. After drying all endarterectomy lipid samples, Iml of Solvent A
(hexoisopropanol and H20) was added to each sample and vortexed.
HPLC fractionation of lipids: Fractionation of lipids was only carried out on
endarterectomy samples. Lipid extracts from plaque samples were derivatized directly
without intervening HPLC fractionation. Separation of lipid extracts was carried out on a
LiChrosorb SI-60 column (IOmm x 25 cm, silica gel) eluted isocratically using solvent A
(hexane: isopropanol: water, 6:8:0.75, v/v/v). Lipid extracts from endarterectomy
samples were dissolved in solvent A (Iml) and 200 JlI injected per column run. The
column was regenerated by running solvent A for 30 minutes. The remainder of the
dissolved lipid extract was fractioned in 200J.lI increme'nis until the entire pooled lipid
sample had been fractionated. Once all of the lipid samples had been fractionated, only
fractions #28-#36 were pooled for sodium methoxide treatment, whereas the remaining
HPLC fractions were discarded. After drying the pooled HPLC fractions #28-#36, the
pooled lipid was dissolved in 200 JlI oftetrahydrofuran and 4·00 J.lI of sodium methoxide.
The samples were heated to 50°C for 15 min. after which the hydrolyzate was
supplemented with 100 JlI of glacial acetic acid and 2 ml of water. The samples were
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extracted twice with 2 ml of chloroform and the organic extracts dried under nitrogen.
The sodium methoxide hydrolysis was used to eliminate most phospholipid
contamination in fractions expected to contain the bacterial ceramides of P. gingiva/is.
Ceramide analysis by gas chromatography-mass spectrometry: The pooled lipid
fractions from individual HPLC fractionated extracts of carotid endarterectomy samples,
and aliquots of the tooth lipid, plaque and bacterial samples were treated with 40 JlI ofbis
trimethyl silyl trifluoroacetamide (BSTFA) and allowed to stand overnight. The lipid
derivatives were then analyzed on a Hewlett-Packard 5890 gas chromatograph interfaced
with a 5988A mass spectrometer. Complex lipid extracts were applied to an SPB-1
column (0.1 nun film x 0.25 nun x15 m, Supelco, Inc., State College, PA). Complex
lipid samples were injected with the inlet block at 31Ocousing the splitless mode with a
temperature program of 1QOC/min from 200°C to 30QoC followed by 5°C/min to 310°C
and 4 min at 31 DOC. The mass spectrometer was used in the electron impact ionization
mode with the ion source temperature of200Co, an electron energy of70eV and an
emission current of 300mA. Bacterial ceramides were identified by selected ion
monitoring for the characteristic ions of ceramides recovered from P. gingiva/is.
Bacterial growth of B. tragi/is, B. forsyth us, P. intermedia and Capnocytophaga
species: Type strains of B. forsythus, B. fragi/is, P. intermedia, C. gingiva/is,
C.sputigena, and C. ochracea, were grown in culture medium on blood agar plates. Dr.
Paulette Tempro provided samples of Capnocytophaga and Prevote//a intermedia
bacterial samples for this study. Dr. Sigmund Socransky provided the sample ofB.
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forsythus used in this study. B. fragi/is and P. gingiva/is were grown in basal medium
included 109 yeast extract, 109 trypticase peptone, 109 biosate peptone, 19.2 g Brain
Heart Infusion, 40ml salt solution, .2 ml Vitamin K, lOml hemin, and 960 liters of
distilled water as described in the VPI Anerobic Laboratory Manual (eds., L.V.
Holdeman, E. P. Cato and W.E.C. Moore). The salt solution contained O.2g CaCl2
(anhydrous), 0.2g MgS04(anhydrous), l.Og K2P04, l.Og KH2C03, 109 NaHC03 and 2g
NaCl. Bacteria were passaged after three days of growth in progressively larger vessels
of culture medium. When bacterial cultures had reached maximal growth, bacteria were
centrifuged and lyophilized before lipid extraction.
Results
HPLC fractionation of lipids ofPorphyromonas gingiva/is revealed that the
ceramides A and B are recovered in fractions 31-35 as shown in Figure 1. The structures
of these ceramides were previously described in detail (See Figure 7). HPLC
fractionation of lipids pooled from carotid endarterectomy samples revealed that the
majority of the lipid is recovered in fractions 7 and 8. Additional characterization of
these HPLC fractions revealed that the majority of the either fraction 7 or 8 lipid consists
of cholesterol (data not shown). Ceramides C and D ofP. gingiva/is shown in Figure 1
therefore coelute with cholesterol and further purification was not attempted in this
investigation. Therefore, identification of these bacterial ceramides in carotid lipid
extracts was considered to be futile due to the overwhelming contamination with
cholesterol. However, ceramides A and B elute in a region of the HPLC chromatogram
where little lipid is recovered (See Figure 2). Additional preliminary evidence has
demonstrated that the lipids of P. gingiva/is eluting in fractions 30-35 contain significant
amounts of phospholipids, particularly phosphatidylethanolamine, in addition to
ceramides A and B. It is expected that the mammalian lipids of carotid endarterectomy
samples eluting in the region of ceramides A and B will interfere with detection of these
ceramides or at least contaminate the ceramides to a significant degree. Phospholipids
contain fatty acids in ester lirlkage to glycerol and these ester-linked fatty acids can be
removed using base catalyzed hydrolysis reactions. The resultant phosphoglycerol base
is water-soluble and does n6t contaminate the ceramides recovered in organic extracts
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after basic hydrolysis. This procedure significantly reduces the phospholipid
contaminants in the HPLC fractions containing ceramides A and B.
The primary agent used for basic catalyzed hydrolysis ofesters is sodium
methoxide. Treatment of pooled HPLC fractions with sodium methoxide is expected to
hydrolyze phospholipids without affecting the ceramides. Figure 3 shows the recovery
of ceramides A and B in fractions 30-32 from an additional HPLC separation ofP.
gingiva/is lipids that occurred months after the separation shown in Figure 1. This
pooled fraction was treated with sodium methoxide and the resultant lipids repurified by
HPLC (Figure 4). GC-MS of the repurified lipid products revealed that ceramides A and
B are not affected by the sodium methoxide treatment yet the amount of contaminating
phospholipid was substantially reduced (data not shown). This approach was applied to
the pooled HPLC fractions of lipid extracts from carotid endarterectomies. However, in
order to ensure that ceramides A and B were recovered in the HPLC fractionated lipids of
carotid endarterectomies, fractions 28 through 36 were pooled and subjected to sodium
methoxide treatment for each carotid lipid sample analyzed.
Using this approach, lipid extracts fronl six carotid endarterectomy samples were
fractionated by HPLC, fractions 28 through 36 were pooled and hydrolyzed and the
resultant lipids were treated with BSTFA to produce trimethylsilyl-ether derivatives of
ceramides A and B. GC-MS analysis included selected ion monitoring for the specific
ions characteristic for ceramides A and B shown in Figure 3 and 4. The temperature
dependent retention time of the lipid derivatives also provided additional confirmation of
the recovery of ceramides A and B.
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Selected ion monitoring demonstrates that lipid extracts from caotid
endarterectomy samples #1, #2, #5-#8 (Figure 5-10) contain ions consistent with lipids
recovered in P. gingivalis HPLC fractions #30-#35 (Figures 3 and 4). These ions are
characteristic for ceramides A and B of P. gingiva/is. The total ion chromatogram ofP.
gingiva/is lipids from HPLC fractions #30-#32 demonstrated significant peaks at
retention times of 10.3 min. and 9.9 min., which correspond to the gas chromatograph
retention times where the M-15 rn/z ions of ceramides A (695 rn/z) and ceramide B (681
rn/z) are detected. The selected ion chromatograms for these specific ions clearly
demonstrate recovery of ceramides A and B at almost identical retention times to the
respective M-15 ions recovered in P.gingivalis lipid extracts. The coelution of all
characteristic ions for ceramides A and B within each endarterectomy lipid sample
indicates contamination with these ceramides of P. gingivalis. Stated another way, the
695 rn/z ion corresponds to ceramide A which has lost a methyl group (15 atomic mass
units) and is identified by the major peak seen at retention time 10.3 min in the selected
ion chromatogram. The other characteristic ions coeluting with the 695 rn/z peak indicate
where ceramide A undergoes alpha cleavage and each ion represents the mass of a
specific positively charged cleavage product. Viewing the total ion chromatogram from
endarterectomy #1 (Figure 11) reveals major peaks at retention times 10.2 min.-10.8 min.
If this total ion chromatogram is scanned for spectra corresponding to that of ceramide A,
a small shoulder eluting at 10.8 min (indicated by arrow) demonstrates all the
characteristic ions found in ceramide A of P. gingiva/is (See Figure 11).
The plaque samples pooled from each patient were analyzed for the ions
characteristic for ceramides A and B. Plaque samples from patients #1, #2, #5-#8
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revealed the presence of both ceramides A and B but in lower ion abundances than that
observed in their respective endarterectomy samples (Figures 12-17). This fmding
suggests that the bacterial lipids are present in relatively low amounts in subgingival
plaque samples. M-15 m1z ion peaks corresponding to ceramides A and B were
identified in the pooled plaque from patient #5 at about 10 min for the 695 m1z ion and
about 9.8 min for 681 m1z ion. The same was observed for plaque samples #6-#8. Ions
383 m1z and 327 m/z were the only ions suggesting the presence of ceramides A and B in
pooled plaque from patient #6. Samples #7 and #8 revealed peaks for 681 m1z (ceramide
B) but in relatively low abundance.
Tooth lipid samples were also obtained from calculus-contaminated teeth
recovered of patients undergoing full mouth dental extractions due to generalized severe
chronic periodontitis. Recovery of the 695 and 681 m1z ions in one of these tooth lipid
extracts was reported previously by Nichols, 1998 [7]. However, all characteristic ions
for ceramides A and B were not reported for these tooth lipid extracts. For this
experiment, aliquots of each pooled tooth lipid extract recovered from two individual
patients were treated to form trimethylsilyl derivatives and subjected to selected ion Ge-
MS analysis. This analysis revealed that the tooth lipid samples contain bacterial
ceramide lipid products very similar to those recovered in carotid endarterectomy
samples. The characteristic ions for ceramides A and B were observed at approximately
the same retention times, ceramide A; 10.3 min. for 695 m1z and ceramide B; 9.8 min. for
681 m1z (Figures 18-19).
The periodontal examination data collected from each patient demonstrated
several important findings. First, many of the patients had less than half of their original
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teeth present and in two of the patients only 7 teeth remained. Second, all patients
demonstrated significant recession, clinical attachment loss and deep probing depths.
Table 1 reveals the mean clinical attachment and number of remaining teeth for all
patients included in the study.
In order to clarify which organisms might contribute ceramides A and B to artery
walls, the next experiments examined lipid extracts from several periodontal pathogens
that are phylogenetically related to P. gingivalis. Lipid extracts from Bacteroides
forsythus (Tanarellaforsythensis), Prevotella intermedia, and B. fragi/is were evaluated
by electron impact, total ion GC-MS analysis for lipid peaks corresponding to ceramides
A or B (Figure 20). This analysis corresponds to the type of analysis shown in Figures 3
and 4. Mass spectra of specific lipid peaks revealed that ceramide B but not ceramide A
is clearly recovered in all species examined except for the Capnocytophaga species
(Figures 21-26). It would appear that at least several periodontal pathogens are capable
of synthesizing ceramide B and therefore all could participate in contamination of artery
walls at sites of atheroma formation. The Capnocytophaga species did not reveal the
presence of any of the ceramides being studied and thus will not be discussed further
(Figures 24-26). Of note, B. forsythus, P. intermedia, and B. fragi/is also produce
ceramide A as detected using selected ion monitoring for its characteristic ions (Figures
21-23). Selected ion monitoring is considerably more sensitive in detecting specific ions
when compared with total ion acquisition because the dwell time for detection of each ion
is much greater with selected ion monitoring. Therefore, the sensitivity of detection of
specific ions is substantially increased with selected ion monitoring. This approach was
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used to evaluate the relative abundances of ceramides A and B in the bacterial species
under evaluation.
The ratios of major ceramides A and B, detected by 695 m/z and 681 m/z ions,
respectively, were evaluated llsing selected ion monitoring for the lipid extracts from
endarterectomy, tooth lipid, and bacterial samples. The abundance ratios of the 695 m/z
to 681 m/z ions reveals that fractions #30-#36 of P. gingiva/is (Figure 27), all of the
carotid endarterectomy samples and the tooth lipid samples have similar abundance ratios
of 695 to 691 m/z ions (Figure 28). However, lipid extracts of B. fragi/is, B. forsythus,
and P. intermedia demonstrated lower amounts of the 695 m/z ion relative to the 681 m/z
ions suggesting that these organisms are not major contributors of these ceramides to
artery walls but rather P. gingiva/is is the major contributor (Figure 29). Calculation of
the ratio of ion peak areas for the various categories of lipid extracts also confirmed this
observation as shown in Table 2.
P. gingiva/is was treated with sodium methoxide (NaOCH3), as demonstrated in
Figure 4, to reduce the phospholipid contamination of the lipid constituents in this lipid
isolate. This did not affect the recovery of ceramides A or B and in fact eliminated
backround noise in the chromatograms creating a much sharper image of the peaks
corresponding to the specific ceramides. Following HPLC fractionation and pooling of
appropriate fractions, all endarterectomy lipid samples used in this study were treated to
reduce phospholipid contamination and facilitate the identification of ceramides. Finally,
approximately 20 ml of Brain Heart Infusion! Basal Medium was extracted for lipids and
approximately 1 mg of lipid was treated with BTFSA. GC-MS analysis of this lipid
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preparation revealed that ceramides A and B are not present in the Basal Medium used to
prepare anaerobic organisms ( Figure 30).
Discussion
The association between cardiovascular disease and periodontal disease has been
extensively studied and unfortunately, like so many other systemic links to periodontal
disease, a true causal relationship has yet to be discovered. In a 7-year prospective study,
dental disease was a significant predictor of coronary events leading to death after
controlling for known coronary heart disease risk factors [47]. To date there have been
no known documented randomized clinical trials that have examined prevention and
treatment of periodontal disease and its effects on cardiovascular disease. On the
contrary, many prospective or retrospective studies have suggested a causal relationship,
but no definitive mechanism has been forthcoming to explain their findings. Most of the
prospective or retrospective studies, Mattila, Beck, Offenbacher, DeStefano, Kinane,
have confirmed a relationship between periodontal disease and cardiovascular disease
whereas others have not [13,47,48,50]. Joshipura et ale found no relationship between
periodontal disease and the incidence of heart disease after adjusting for other known risk
factors [49]. Hujoel et ale failed to make this association and indicated that removal of all
teeth did not alter the risk for heart attack when compared to age-nlatched subjects with
periodontal disease. After extensively adjusting for confounding factors, for example
even infections associated with periodontal disease, they found no association [15].
These later studies may be criticized from a number of perspectives. The first is that the
epidemiologic studies may over adjust for confounding factors and thereby obscure the
role of specific risk factors. In the absence of convincing arguments to the contrary, the
opposite criticism could be raised against those reports that claim a relationship between
periodontal disease and cardiovascular disease. The second issue is the patients may
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have been placed into inappropriate periodontal disease categories in either type of
report. Patients who were healthy at the time of their periodontal exam may have
developed periodontal disease at some later time (years later) and thus were incorrectly
classified. Tooth loss earlier in life could be associated with either caries or periodontal
disease and yet the ascertainment of tooth loss could be incorrectly assigned to or not to
periodontal disease. Also, potential confounders become very critical with moderate level
associations as are generally reported in the positive association reports. Some studies
may be controlling for confounders that are actually influencing periodontal disease.
These limitations cast some doubt on the significance of the reported association between
periodontal disease and cardiovascular disease and more clinical data is needed to
identify the underlying mechanism for this purported relationship between periodontal
disease and cardiovascular disease.
Until now, two general models have been proposed to explain the relationship
between periodontal disease and cardiovascular disease. The first involves a direct
mechanism, where periodontal pathogens are carried in the blood to the site of the
atheroma and accelerate the atheroma formation by invading the artery wall. Another
model proposes an indirect mechanism whereby the periodontal pathogens within and
around the oral cavity instigate an inflammatory reaction that can potentially influence
levels of inflammatory mediators within circulation, and the increased systemic
inflammatory mediators then influence cell activation at atheroma sites, thereby
propagating the formation process. Hazarthy et ale were the first group that demonstrated
contamination of carotid atheromas with genomic products of periodontal pathogens.
This group reported an investigation of 50 human specimens obtained during carotid
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endarterectomy procedures. They found evidence of DNA from periodontal pathogens
using specific oligonucleotide primers in polymerase chain reaction assays [57]. It was
reported that 30% of the surgical specimens were positive for B.forsythus, 26% were
positive for P. gingiva/is, 18% were positive for A. actinomycetemcomitans, and 14%
were positive for P. intermedia [57]. Beck and colleagues found that severe
periodontitis was associated with carotid artery intima-media wall thickness ~lmm, after
adjusting for age, sex, diabetes, LDL cholesterol, HDL cholesterol, triglycerides,
hypertension, smoking, waist-hip ratio, education, and race [11]. Many recent studies
have attempted to explain these observations. One of these studies, looked at serum
lipids and their activity, as a possible cause for the observations reported in the previous
studies. What was the outcome?
Chronic localized infections, for example periodontitis, have profound effects on
cytokine levels locally in the diseased tissue that could alter lipid metabolism locally and
systemically. It has been suggested that elevated cytokine levels might result in
hypertriglyceridemia and elevated lipid oxidation in the systemic circulation. Analysis of
sera from random healthy clinical patients demonstrated significant elevations of serum
lipids and P. gingiva/is antibody titers in patients with periodontitis when compared with
patients without periodontitis [63]. In addition, logistic regression analysis of disease
status with elevated serum lipids and increased P. gingiva/is antibody titers demonstrated
a significant association between disease expression and total serum cholesterol,
triglycerides and P. gingiva/is antibody titer [63]. The association of an elevated
circulating level of lipid state does not permit the establishment that periodontitis is the
cause of these observations. Further investigation of potential influences of regional
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infectious disease of a chronic nature (periodontal disease) and alterations in systemic
risk factors for cardiovascular disease should be pursued from the standpoint of
mechanistic explanations.
Gram-negative organisms, such as Porphyromonas and Bacteriodes species,
colonize the root with the diseased periodontal pocket. The connective tissue forming the
periodontal pocket wall is an immensely vascularized area for introduction of bacteria
and its mediators into circulation and for exchange of immunologic mediators into the
systemic circulation from the surrounding tissue. Bacterial LPS, as mentioned
previously, is impressive in its chemoattractant and activation effects on monocytes.
Atherosclerotic aorta walls are reported to contain monocytes secreting IL-I ~ and TNF-u
[56]. These cytokines enhance lipid accumulation within monocytes as well as promote
significant alterations in cells found transmurally in the artery wall. The idea that lipids
could be biologically active prompted further research to identify whether bacterial lipids
are recovered in atheromas and which organisms are responsible for synthesizing these
lipids. A recent report has identified specific novel ceramides in abundant amounts in a
specific periodontal pathogen, P. gingiva/is. These novel ceramides were also reported to
be absorbed to diseased root swfaces and are recovered in diseased gingival tissue
samples [7]. The present investigation has identified these same ceramides in lipid
extracts of carotid atheromas and has demonstrated that the ratio of the dominant novel
ceramides is virtually identical in laboratory grown P. gingivalis, tooth lipid and lipid
extracts of carotid atheromas.
The major ceramides that are central to this thesis contain a long chain base of
either a 2-amino-1 ,3-nonadecanediol (Ceramide A) or 2-amino-1 ,3-octadecanediol
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(Ceramide B) in amide linkage to C17:1. These are the most abundant free ,ceramides
recovered from P. gingiva/is and up to now have been detected only in P. gingiva/is and
to a small extent in B. forsythus. These novel ceramides are encountered when analyzing
lipids from other periodontal pathogens and organisms of similar genera, but in lower
levels. For example, analysis of the total ion chromatogram from B. fragi/is shows
several major peaks at different retention times in comparison to the major peaks found
on the total ion chromatogram for P. gingiva/is, but only one of the major ceramides
(681m/z) is found and its retention time is longer than that observed with the comparable
ceramide from P. gingiva/is. An additional important observation is that the ions
characteristic for ceramide B of P. gingiva/is are not all recovered coeluting with the
681m/z ion product from B. fragi/is. Therefore, the 681 m/z lipid of B. fragi/is may
represent a structural isomer of ceramide B. This observation is important when
examining ceramide lipid profiles in endarterectomy samples of patients with
atherosclerosis. The total ion chromatogram of endarterectomy #1 reveals not only a
very similar retention time for ceramide A (695m/z) as compared to P. gingiva/is, but
also reveals the specific ions characteristic for that one ceramide and ceramide B. If
these ceramides were derived from B. fragi/is, the ceramide ion spectra would more
likely be representative of ceramide B rather than ceramide A. Because of the striking
similarity between the ion chromatograms of both P. gingiva/is and the endarterectomy
sample, it is likely that P. gingiva/is is the major contributor of bacterial ceramides
recovered in carotid atheromas.
This investigation identified lipid derivatives with ion fragmentation spectra
consistent with the presence of ceramides A and B in all carotid atheromas. HPLC
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fractionation of lipids from P. gingiva/is revealed that the most abundant free ceramides
are recovered in HPLC fraction 31-34 (See Figure 1). These HPLC fractions contain the
free ceramides of P. gingiva/is consisting ofCI?:l (a-~ unsaturated) and either an 19
(ceramide A) or 18 (ceramide B) carbon long chain base. These ceramides were also
detected to a small extent in GC-MS results from B. forsythus, B. fragi/is, and P.
intermedia. HPLC fractionation of endarterectomy lipid extracts used an identical but
different HPLC column than was used to identify ceramides A and B in P. gingiva/is
fractionated lipids. The fractionated endarterectomy lipids were pooled from fractions
28-36 in order to maximize the recovery of ceramides A and B for GC-MS analysis.
GC-MS analysis included selected ion monitoring for specific ions (695, 512, 455, 383,
327 and 258 m/z) of ceramide A and ions (681, 498, 455, 383, 313 and 258 m/z) of
ceramide B, thus confirming the presence of these ceramides in lipid extracts of carotid
endarterectomies. Graphic representation of specific ions, corresponding to locations
along the molecule where specific carbon to carbon bonds undergo cleavage, reveals
almost identical retention times for ceramides A and B recovered from all six
endarterectomy samples as well as the novel ceramides of P. gingiva/is. Other organisms
examined, B. forsythus, B. fragi/is, P. intermedia, and Capnocytophaga species, reveal
significant lipid peaks either at different retention times or the presence of primarily the
lesser abundant ceramide recovered from P. gingivalis (ceramide B). Therefore, these
bacteria produce either different isomers of the ceramides recovered in P. gingiva/is or
synthesize ceramides A and B in substantially different proportions than that observed in
P. gingiva/is. This evidence suggests that P. gingiva/is is the major contributor of
ceramides A and B to carotid atheromas.
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The results from the plaque samples of the six patients examined in this study
reveal the presence of the specific ceramides in some plaque samples, particularly
plaque sample #5, but not in abundant amounts. This observation could be attributed to
the methods utilized to obtain the plaque samples. It is possible that the paper points
used to collect the samples did not collect enough of a microbial sample to allow
detection of ceramides A and B. This does not exclude the possibility that the lipids
being examined are not present in significant amounts in subgingival plaque samples
around the remaining teeth. Analysis of the tooth lipid samples in the present study again
reveals specific ions consistent with ceramides A and B, as detected in endarterectomy
samples. The tooth lipid samples were obtained from teeth contaminated with significant
amounts of subgingival calculus. Because subgingival calculus represents entombed
subgingival organisms that accumulate over an extended period of time in a mineralized
matrix, the lipid composition of tile subgingival calculus probably more closely
represents the historical exposure of the subject to bacterial lipids. Sampling of
subgingival plaque is probably a better indicator of the present day harboring of specific
pathogens but does not provide the cumulative measure of exposure to the bacterial
lipids.
The clinical data from the periodontal examinations revealed that most of the
patients retained less than half of their original dentition, and in two cases only 7 teeth
were present. Clinical attachment levels revealed significant amounts of attachment loss
and chronic inflammatory disease. That the patients presented with significant attachment
loss indicates that these patients had periodontal disease at some point in time and that an
environment existed at some point that was conducive to bacterial colonization of teeth
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and systemic introduction of bacteria. No clear correlation could be made between the
results from the ion chromatograms of the endarterectomy lipid samples and the clinical
results. All patients presented with significant amounts of bacterial lipid in atheroma
lipid extracts and all presented with significant evidence of disease.
The final portion of the study compared the ratios of the major ions of ceramide
A and B (695m/z and 681m/z) for all endarterectomy samples, tooth lipid samples, and
bacterial samples from B. fragi/is, B. forsythus, and P. intermedia. Capnocytophaga
species were not included in this analysis because previous total ion chromatograms
revealed insignificant recovery of ceramides A and B and thus it can be assumed that
these organisms produce a completely different spectrum of lipids than those observed in
P. gingiva/is. The ion ratios were calculated in order to show the quantitative distribution
of ceramides A and B in the various samples. The endarterectomy lipid extracts
demonstrated similar ceramide ion ratios as those determined for tooth lipid samples and
P. gingiva/is. The data from B. fragi/is, B. forsythus, and P. intermedia also revealed
that these bacteria can synthesize ceramides A and B but not at the same relative
abundances as those found in lipid extracts from diseased teeth, carotid atheromas and P.
gingiva/is.
It is known from previous investigations that specific classes of ceramides from
P. gingiva/is potentiate IL-l~-mediated release ofPGE2 from gingival fibroblasts in
culture. The combination of bacterial lipid penetration into gingival tissues and a chronic
inflammatory response is therefore expected to substantially potentiate prostaglandin
secretion from gingival fibroblasts resulting in an intensified host reaction that may tip
the balance toward tissue degradative processes associated with adult periodontitis. A
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previous study has demonstrated that DNA of periodontal pathogens is present in a
relatively low percentage of carotid athereomas. The present study revealed that the
lipids ofP. gingiva/is are consistently recovered in carotid atheromas in contrast to the
bacterial genomic product recovery. This evidence together with the distribution of
ceramides recovered in atheromas suggests that the bacterial ceramides are derived from
a common origin. Data presented in this thesis confirm that other bacteria can synthesize
ceramides A and B but not in the proportions recovered in atheromas suggesting that P.
gingivalis is the predominant source of the ceramides recovered in atheromas. However,
this is not to say that other periodontal pathogens and non-oral organisms do not
contribute ceramides to atheromas. Potentially other sites within the body could
contribute bacterial lipid to the atheromas, Le. the intestines.
The bacterial ceramides A and B are readily recovered in carotid endarterectomy
samples and this observation suggests that human tissue does not easily degrade these
molecules, probably due to the complexity of their structures. A possible mechanistic
explanation for the transport of bacterial lipids to the artery walls could be through
circulating white blood cells. A model is envisioned where bacteremias with periodontal
pathogens are cleared in the blood through the action of phagocytes. The phagocytes
effectively clear and kill the organisms in the blood but the bacterial lipids remain in the
phagocyte cell walls because the lipids are not cleared through metabolic breakdown
processes. These contaminating bacterial lipids retain biological activity and in the case
ofmonocytes, these bacterial lipids potentiate monocyte secretory and activation
processes. Such a process would be expected to render moncytes more adherent and
hyper-reactive to inflammatory stimuli. Monocytes contaminated with bacterial lipids
64
would be have a greater tendency to adhere to arterial walls and the direct contact
between monocyte cell membranes and endothelial cell membranes allows diffusion and
deposition of the bacterial lipids into the arterial wall cells. This model is supported by
recent preliminary evidence indicating recovery of bacterial lipids in circulating white
blood cells from patients with chronic periodontitis. Of note, serum from patients with
severe periodontitis does not contain measurable levels of3-0H iC 17:0 indicating that the
organisms and/or their lipid products (LPS, ceramides) are not present in the serum of
these patients.
It is beyond the scope of this study to reveal a true causal relationship between
periodontal disease and cardiovascular disease, but the evidence discovered from the
analysis of endarterectomy samples from patients with atherosclerosis supports the idea
P. gingiva/is is contributing to atheroma formation. Bacterial lipids appear to originate
from the oral environment but could also come from other areas of the body, as depicted
in data from the total ion chromatograms of B. fragi/is, B. forsythus, and P. intermedia.
This study was qualitative in nature but indicated that all atheromas are contaminated
with bacterial ceramides. Data that has not yet been published indicates that bacterial
fatty acids and long chain bases are present in lipid extracts of more than 50
endarterectomy samples analyzed. These findings lend further support to the importance
of the observed contamination of carotid atheromas with bacterial ceramides reported in
this thesis.
Additional experiments are planned that will directly administer the purified
bacterial ceramide fractions to murine strains that are known to develop atherosclerosis.
These planned experiments should provide a more definitive answer to the importance of
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the bacterial lipids in the atherogenic process. Ultimately, the information that has been
presented in this thesis may impact on the way clinicians view patients with
atherosclerosis and the attention health care providers should give to oral infections. It
may eventually become a therapeutic recommendation..that antibiotics or other
antimicrobial agents be used to reduce the oral levels ofP. gingiva/is. Whatever the
outconle of research in the area may be, the fact is that bacterial lipid contamination of
human tissues extends beyond oral sites and this bacterial lipid contamination may have
significant long term consequences for the host. More research needs to be conducted in
this area to define the mechanisms of bacterial lipid contamination of non oral tissues and
the biological consequences of this contamination.
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Flow Diagram
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Extract lipids from carotid endarterectomies using the
phospholipid extraction procedure of Bligh and Dyer.
Separate lipids using isocratic HPLC and a silica gel column in order
to separate cholesterol from the bacterial ceramides of interest.
Pool HPLC fractions expected to contain the bacterial
ceramides of interest and dry the samples.
Treat the pooled lipid sample with sodium methoxide in
order to destroy the contaminating phospholipids.
The lipids extracted from the basic hydrolysis reaction with
BSTFA and allow to sit overnight.
Analyze lipid derivatives for bacterial ceramides using GC-MS in
the selected ion monitoring mode. The ions monitored are
specific for the bacterial ceramides of interest.
Flow Diagram 1. Flow diagram indicating the experimental design in
analyzing the lipid extracts of carotid endarterectomy samples. Bacterial,
plaque and tooth lipid samples were processed in a similar manner to the
endarterectomy lipid samples.
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Tables
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Patient number Number of Mean Clinical Mean Probing
Remaining Teeth Attachment Loss Depth (mm)
(mm)
1 19 4.5 3.2
2 14 2.8 2.9
5 26 3.7 3.1
6 7 4.6 2.6
7 26 3.5 2.6
8 7 4.5 3.0
Table 1: The number of remaining teeth, mean clinical attachment loss in
mm and mean probing depths in mm for each patient.
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LIPID SAMPLES ION ABUNDANCE RATIO(695 m/z/681 m/z)
Endarterectomy (0 ±SD) 0.9231 ±0.4042 (n=6)
Tooth (0 ±SD) 0.8148 ±0.3844 (n=2)
B·fragiiis 0.3364
P. intermedia 0.5319
B. forsythus 0.4245
P. gingivalis 0.8333
Plaque 0.8142
Table 2. Comparison of the ion abundance ratios for ions 695 m/z to 681
m/z, graphically represented in Figures 27-29, in lipid samples isolated from
endarterectomy, bacterial, plaque and tooth samples. These results show the
similar ion ratios (695m/z/681m/z) between lipid extracts of
endarterectomy, tooth lipid, plaque and P. gingiva/is samples.
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Figures
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FIGURE 1. Recovery of ceramide classes in HPLC fractionated lipids of P.
gingivalis. Lipids were extracts from P. gingivalis using the method of
Bligh and Dyer and fractionated by HPLC using isocratic separation on a
silica gel column. A sample of each fraction was treated with BSTFA and
analyzed for specific ceramide classes by using selected ion monitoring for
the M-15 rn/z ion characteristic for each ceramide.
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FIGURE 2. The HPLC fractionation of lipids pooled from carotid
endarterectomy samples revealing the greatest mass of lipid at fractions 7
and 8. Previous investigations revealed that this region is contaminated with
abundant amounts of cholesterol and identification of bacterial ceramides in
this area is difficult.
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Figure 3. The total ion chromatogram of HPLC fractions 30-32 of
P. gingivalis lipids before sodium methoxide treatment. A sample
of the pooled HPLC fractions was treated with BSTFA and
subjected to GC-MS analysis as described in the methods section.
The specific ions characteristic for ceramide A (peak emerging at
10.312 min) and ceramide B (peak emerging at 9.929 min) are
shown. The characteristic ions for ceramides A and B result from
alpha cleavage reactions as well as intramolecular reorganizations.
Ions were detected in the electron impact mode and therefore
represent only positive ions.
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Figure 4. The total ion chromatogram ofHP~C fractions 30-32 of
P. gingivalis lipids after treatment with sodium methoxide
treatment. In order to remove most contaminating phospholipids,
the pooled lipid fraction depicted in Figure 3 was treated with
sodium methoxide as described in the Methods. The hydrolysis
products were extracted into chloroform, dried and treated with
BSTFA. The specific ions characteristic for ceramide A (peak
emerging at 10.312 min) and ceramide B (peak emerging at 9.929
min) were recovered in the sodium methoxide treated fractions as
show.n.
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Figure 5: Selected ion chromatograms demonstrating recovery of
ceramides A and B in lipids extracted from carotid endarterectomy
sample #1. Lipids were extracted using the method of Bligh and
Dyer and separated using isocratic HPLC as described in the
Methods. HPLC fractions 28-36 were pooled and treated with
sodium methoxide. The resultant hydrolysis products were treated
with BSTFA and subjected to GC-MS analysis. Selected ion
monitoring for the characteristic ions and retention times were
used to identify ceramides A and B (See Figures 3 and 4),
indicated by a and b respectively, in the carotid atheromas.
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Figure 6: Selected ion chromatograms of HPLC lipid fractions
28-36 recovered from carotid endarterectomy sample #2. See
Legend of Figure 5 for experimental details.
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Figure 7: Selected ion chromatograms of HPLC lipid fractions 28-
36 recovered from-carotid endarterectomy sample #5. See Legend
of Figure 5 for experimental details.
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Figure 8: Selected ion chromatograms of HPLC lipid fractions 28-
36 recovered from carotid endarterectomy sample #6. See Legend
of Figure 5 for experimental details.
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Figure 9: Selected ion chromatograms of HPLC lipid fractions 28-
36 recovered from carotid endarterectomy sample #7. See Legend
of Figure 5 for experimental details.
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Figure 10: Selected ion chromatograms of HPLC lipid fractions
28-36 recovered from carotid endarterectomy sample #8. See the
Legend of Figure 5 for experimental details.
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Figure 11. The total ion chromatogram of HPLC fractions 28-36
recovered from carotid endarterectomy sample #1. This lipid
sample was prepared as described in the Legend of Figure 5 but
was analyzed using total ion acquistion (150-800 m/z) rather than
selected ion monitoring. similar to Figures 3 and 4. The black
arrow indicates a small shoulder eluting at 10.8 min where the
characteristic ions for ceramide A of P. gingivalis are recovered.
See Figures 3 and 4 for spectra indicating the characteristic ions
for ceramide A.
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Figure 12: Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #1. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
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Figure 13. Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #2. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
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Figure 14. Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #5. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
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Figure 15. Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #6. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
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Figure 16. Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #7. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
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Figure 17. Selected ion chromatograms of lipids extracted from
pooled subgingival plaque samples isolated from patient #8. Ions
characteristic for ceramide A and ceramide B, are indicated by a
and b, respectively.
105
Ion 695.09 nu. ;I"oa \/3: PLOe. D
2299
2279
2269
22S9f1N~~~~'ltA~iiJt'WI~~~A1A~AJ~A
2248
2288
2278
2269
225a
2248
Ion G91.8a ••U. frOIl V3:PLOB.D
u
c:
."
c:
~
.0
a:
Ion 512.8e UU. floo. V3:PL08.D
2289
2270
22&9
2259 n'1~rWJ~~~V1iJ~lvt.~~Jwrv'A,J~jA..,A.UjN4j~
2249
u
u
c:
."
c:
::J
.0
a:
Ion 498.8e ..u. fro. V3:PL08.D
2281
2279
22&a
2258rtriJ"fJ~~.,,~~-vJ'~~~~~JJI'~'utJNI
2249
Ion 455.9a ••u. fl"n V3:PL08.D
2289
227e
226e
2250
224a "----.........__..,.....__,..--__--, ---__--..........,
& 9 19 12 14 1& 19
TIlle e.in.)
228'1 Ion 455.88 .au. fro. V3:PLQ8.D
2278
22&8
2258
2249 "--........----.-..,.....--,..--_._........,,........_---r__.-..,. __
& 8 19 12 H 16 18
T'lle (1I1n.)
Ion 383.e8 nu. fl"u V3:PLQS.D
Ion ~58. ee .IIU. flooa \/3: PL08. 0
29]L......--r----.....--==.......,.......~ ~
19 12 14 16 18
Tille (.In. )
Ion 313.8a .IIU. 11"0. \/3: PL08. D
~
18 12 14 16 18
Ti lie C.ln. )
Ion 259.99 ..U. IrOIl V3: PLQa. D
:=:~
18 12 14 16 18
TIll. Cllin. )
b
2335
1
JL.....--,.-~~ ~
Ion 383. rae aIIU. fro. V3: PLOa.O
u 3_tc:
-0
c: 2B9~
::J te89
.0 9ex:
S
u 29] ~c-0C:t~
u
c:
."
c:
::J
.0
ca::18
19
1816
a
10 12 14
TIlle (.in.)
19 12 14 16
Ti lie (Illin. )
Ion 327. ea ••u. ftou V3: PLQ8. D
~~
Ie 12 14 16
T, ..e e.in. )
3gest:
2eea
18ee
S --------..,.....--,..---.....,.---""""T""----..,6
u
c:
-0
c:
:»
.0
ex:
u
u
c:
."
c:
::J
.0
a::
Figure 17
106
Figure 18. Selected ion chromatograms of lipids extracted from
teeth laden with subgingival calculus. Teeth were extracted from a
single patient with generalized severe chronic periodontitis and the
teeth were extracted using the method of Bligh and Dyer. A
sample of the lipid extract was treated with BSTFA and subjected
to GC-MS analysis. Characteristic ions for ceramides A and Bare
shown in a and b, respectively.
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Figure 19. Selected ion chromatograms for ceramides A and B
recovered in tooth lipid extract from another patient. The lipid
extract was obtained and processed as described in Figure 18.
Characteristic ions for ceramides A and B are recovered in this
tooth lipid extract as shown in a and b, respectively.
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Figure 20. The total ion chromatograms of lipid samples obtained
from B.fragilis, B.forsythus, and P. intermedia. These organisms
were grown in pure culture and lipid extracts were obtained using
the method of Bligh and Dyer. The lipid samples were treated
with BSTFA and subjected to GC_MS analysis using the total ion
acquistion mode. Lipid extracts of B.fragilis, B.forsythus, and P.
intermedia are indicated by a, b, and c, respectively. Comparison
of these ion spectra with those shown in Figures 3 and 4 indicates
that ceramides A and B are not prominent in these bacterial
isolates.
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Figure 21: Selected ion chromatograms of the lipid extract from B.
jragilis. The lipid extract shown in Figure 20a was subjected to
selected ion monitoring for characteristic ions and retention times
of ceramides A and B, indicated by a and b, respectively.
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Figure 22. Selected ion chromatograms of the lipid extracts from
B. forsythus. The lipid extract shown in Figure 20b was subjected
to selected ion monitoring for characteristic ions and retention
times of ceramides A and B, indicated by a and b, respectively.
115
Ion &95.99 .au. froa Y3:BF'O~SSIH.D
m;I A _
Ion 681.89 ••u. fro.. V3:BrORSSIH.D
6B9815988
4989 .A
:U88
--------' -----------
18IS18 12 14
Tille (aln.)
Ion "55. B8 .au. froa V3: BF'ORSSIH. D
Ion 498. B8 u'u. fro. V3: BF'ORSSIH.D
6999
1 1588B4B993BB9 '________ _ _
seBelSBBB
4B88
3888
.....~__.,....~~~~:a.-~--~--- ............___
u
u
c
.
."
C
:J
J:J
a:
18
i
1619 12 1<4
T,ae ( .. In.)
Ion 512.99 ••u. fro .. V3:BF'ORSSIH.D
4ge91
3seB 1
3989
2Salil
"------_..... -----------
Ion 455.09 .au. fro. Y3: BF'ORSSIH. DApi
u
u
c;
.
"c;
:J
~
a:
Ion 393.90 UlU. ~ roa Y3: BF'ORSSIH. D
1.9
E
i-
51
5.9E+4
________--./\..A _
Ion 327.90 aIllU. froa Y3:BF'ORSSIH.D
~ 1.9£+51 I,
l 5.9£+4 , -Jl.......... _
Ion 383. e9 ••u. ","Oil V3: BrORSSIK. D
2.8£+511.5[+5
1.8£+5
5.8£+4 Io..- ~ _
Ion 313.88 .au. fro. V3: BF'ORSSIH. D
~ 2.B[+51 A; 1.5£+5
~ 1.9E+5
~ 5.8£+4a: "'__ -- _
Ion 259.80 ..au. frOIl V3:BF'ORSSIH.D
18
,
16
Nb&
18 J2 14
Tiae (ain.)
2.8[+511. 5E+5
l.e[+5
5.8E+4
-~......--.,.......~~~~_ ........-...----.......----._-
b
Ion 258.99 ••u. fro. V3:BF'ORSSIH.O
1816
a
18 12 14
Tlae (aln.)
1.9£+51
5.9EH
--~......--..-..~-.,......;.~~ .....--......,._..-.....,.----
Figure 22
116
Figure 23: Selected ion chromatograms of lipid extract from P.
intermedia. The lipid extract shown in Figure 20c was subjected to
selected ion monitoring for characteristic ions and retention times
of ceramides A and B, indicated by a and b, respectively.
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Figure 24: Selected ion chromatograms of lipid extracted from C.
gingivalis. C. gingivalis, generously provided by Dr. Paulette
Tempro, was extracted for lipids as described previously and
subjected to selected ion monitoring for ions characteristic of
ceramides A and B.
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Figure 25: Selected ion chromatograms of lipid extracted from C.
ochracea. C. ochracea, generously provided by Dr. Paulette
Tempro, was extracted for lipids as described previously and
subjected to selected ion monitoring for ions characteristic of
ceramides A and B.
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Figure 26: Selected ion chromatograms of lipid extracted from C.
sputigena. C. sputigena, generously provided by Dr. Paulette
Tempro, was extracted for lipids as described previously and
subjected to selected ion monitorillg for ions characteristic of
ceramides A and B.
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Figure 27. Ion abundances for M-15 m1z ions characteristic for
ceramides A and B of P. gingivalis. A sample of HPLC fractions
30-36 of P. gingivalis lipids was treated with BSTFA and
subjected to GC-MS analysis. Selected ion monitoring was used to
identify the M-15 m1z ions characteristic for ceramides A (695m1z)
and B (681m1z) in the individual HPLC fractions. Fracations 30
through 36 are depicted as samples a through g, respectively.
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Figure 28. Ion abundances for the M-15 m/z ions characteristic
for ceramides A and B recovered in carotid endarterectomy lipid
samples. Ion chromatograms for endarterectomy samples #1, #2,
#5-#8 (a through f, respectively), and tooth lipid samples #land #2
(g and h, respectively) were compared for their relative recoveries
of ions 695 m/z and 681 m/z. These figures represent a limited
analysis of selected ion chromatograms depicted in Figures 5
through 10.
127
Ion 681.11 ..... fro. V3:tNDSI"I.D
a
1
18
ret
"
Ion 681.'1 .M. 'r08 V3:£JIDSIP12.D
~l .. ~ \
18 12 14
TI_ (01".)
b
10" U5.18 ._. 're- V3:ENDSIIt2. D
26"
255.
2511
245.
24.
235.
2388225'~"'-""'"""--....,.JV-'......~~--~--
"l
2558
25M
2451
24"
235.
23M225.: ;"'"
6181614
34'"
:U.. 1: .
:::: .
.:::::=c::::::::=c~~.....~:-....- .....- ....- ......,
"·l:UII3111....UH
2488
Ie" "S.II ._. 'ro. V3ItNllSIH5.D
.111' 135H3...
UII
"'"'"-- --
2411
2'1"
U61
234'
23211
2388
2218
22&8 r.-"-...r~""-Nv.cA. ...., 11
I.ft 6U." ._. fro. V3:tND5IItS.D Ion &81.81 • .,. fro. V3:ENDSJJ0t5.D
2111
2388
2368
2341
:::: .
UII
22611 ........__~_.........._-....__
, 8 I' 12 14 I' 18
T... C•• ".)
III1614
J,
l' 12
Ti •• Colft.)
1"'1::
25M
------~---..--.....-------"\
c d
10ft S9S.M ..... f ...o V3:£ND7.D
25Hl 1::::2351
2388
2258 ----- ------~"""~- ...""'''''
rOft 695...... fro. V3IENDI.D
2.11' 1271125115 1
::: ------ --------
10ft 581.88 ..u. fro. V3:tND7.D 10ft 581." .... fr •• V3:EMDI.D
1816II 12 11
Tt. e.t".)
211112'1125n::: L
nil .Q1~~"",,,,,,,,,,,,,,---~:lilICI.........-ol"'''''__
6
+ t
18•J6
::;
14
"·l21S.24112351u ..
....z-.J";
, 8 II. 12
T, .. C.'ft.)
e f
I
II16
L
II 12 14
TI_ r.I".)
10. &II." .... fro. V1rTOOTHL.I2.D
1_ 115." _... f .... V).TOOTHLU.D
::1 I
n. , -..I'l _
::124..
U..
=::c:::-=-.........e:c~=--__==_ .......- .....---__..c1.
10" C'5.H __ • fr•• V3: TOOTHLIl.D
n88':: __-__l _
1." 511." .... Ir•• V3:TOOTHlIl.D
~~l~l~c:-
• II 12 14 .6
Tt_ (.In.)
g h
l?igu~~_~~--------------------L---- ------
128
Figure 29: Ion abundances for the M-15 rnlz ions characteristic for
ceramides A and B recovered in lipid samples from B.fragilis (a),
B.forsythus (b), and P. intermedia (c). These organisms show
lower ion abundances for M-15 rnlz ions characteristic for
ceramides A and B suggesting that these organisms are not
significant contributors of ceramides A and B to artery walls.
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Figure 30: Selected ion chromatogram for the M-15 m/z ions
characteristic for ceramides A and B using a sample of lipid
extracted from Brain-Heart Infusion! basal medium. A sample of
the Brain-heart Infusion/basal medium used to culture the
previously described organisms was extracted for lipid and a
portion of this lipid extract was processed and analyzed by Ge-
MS. Selected ion monitoring for 695 m/z and 681m/z ions
revealed negligible recovery of cearmides A and B in this culture
medium.
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